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Over the past several decades, significant research has been completed in an effort to
understand the impact Type 2 diabetes has on the expense associated with disease treatment and
maintenance, health care industry resources, and prevention of the disease. At the same time
many corporations have taken on the challenge of providing workplace wellness programs to
reduce health care expense associated with chronic illness or unhealthy behaviors and improve
the overall health of employees. Coupling these efforts with the accountable care organization
model established via the Patient Protection and Affordable Care Act, this research determined that
obtaining a positive return on investment for a diabetes workplace wellness accountable care organization
is very difficult but the ability to improve participants management of diabetes is a worthy venture that
should be continued to be evaluated to determine how program variables need to be modified to provide a
positive return on investment.
viii

INTRODUCTION

Fourteen years ago the Institute of Medicine published Crossing the Quality
Chasm (Institute of Medicine, 2001) that called for extensive modifications to the health
delivery system. One of the key modifications identified in the document was “creating
and aligning incentives for quality and increasing the transparency of quality information
for quality improvement, accountability and consumer choice (Damberg, Raube,
Williams and Shortell, 2005). One of the resulting innovations in the organization and
payment for medical care has been the development of Accountable Care Organizations.
Most recently the final ruling for Accountable Care Organizations (ACO) has specified a
model in which provider compensation, initially for Medicare, will utilize a pay-forperformance model. The ACO model “is meant to improve the value of health care
services, controlling costs while improving quality as defined by outcomes, safety, and
patient experience” (McLellan, et al., 2012) The challenge with both the pay-forperformance and ACO model is the ability to demonstrate the reduction in cost of care by
transitioning from episodic care models to preventive care treatment. However, recent
innovations in computer software that aggregate medical care use and cost at the patient
level hold promise for enabling us to identify cost reductions rapidly and with ease.

While payers have been working on models to reorganize the delivery of medical
care to focus on and reward prevention, employers have been developing sophisticated
worksite wellness programs to change the individual worker's behavior toward disease
prevention, in an effort to minimize the expenses associated with lifestyle decisions that
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directly impact the cost of health insurance and health care. Many employers have
expended significant effort to improve health and reduce expense via workplace wellness
programs. When implemented, the majority of workplace wellness programs demonstrate
a cost savings and a focus on lifestyle changes to improve overall health and productivity
of employees. Participation in the programs can be voluntary or established by providing
incentives to employees. The services provided in a workplace wellness program are very
similar to components of effective ACO programs; utilizing disease identification,
coordinated care, and results tracking for the improvement of individual health while
reducing the cost of providing health care.

Thus, worksite wellness programs have contributed to better employee health for
a decade and have shown some financial benefits. However, they have been lacking in
ability to identify the total financial benefits that they produce because they lack the
ability to capture all medical expenditures. ACO’s are innovative structures that
encourage evidence-based medical practice with a focus on prevention. However, most
ACOs lack the ability to provide powerful incentives for patients to change behavior and
have only limited resources for providing individual patient support for change. They do,
however, have sophisticated software tools to aggregate patient utilization and cost data
to measure the financial benefits of an increased focus on prevention. The combination
of a workplace wellness program with incentives and patients support structures, and the
use of an ACO software program to capture expenditures, may enable us to measure the
return-on-investment (ROI) for behavior change over a short (1 year) time horizon. This
study will demonstrate how a workplace wellness program can be combined with ACO
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software to asses ROI in the short term. We will focus this examination on a common,
high cost condition that, when managed well, holds promise for even short-term cost
saving. The best choice for demonstration purposes is diabetes.

Diabetes, specifically Type 2 diabetes, is a disease that impacts a large percentage
of the United States population. Either as a confirmed diagnosed disease, as an
undiagnosed disease, or as an increased potential to develop the disease (Statistics About
Diabetes, 2014). Significant clinical information is available to evaluate individuals with
diabetes or those that are considered pre-diabetic. This information also provides
guidance for appropriate disease management to maintain a healthy lifestyle mitigating
disease progression (Diabetes Care, 2014). Although the prevalence of diabetes is well
documented and the various degrees of the disease can be clinically diagnosed, the
number of individuals diagnosed with diabetes has increased significantly over several
decades (National Health and Nutrition Examination Survey). As such, the health care
costs associated with providing care for individuals with diabetes continues to burden the
United State health care system (American Diabetes Association, 2013). However,
targeted interventions to change patient behavior have shown some short term financial
benefits for patients with diabetes, which makes it an excellent disease for demonstrating
short term financial impacts.

3

Research Question(s)

The main research question for this study is: Can using an ACO commercially
available software tool and a diabetes workplace wellness management program be
combined to identify 1 year ROI in a sample of patients within an average size
institution?

If a ROI cannot be measured at 1 year, a follow-up question will be posed as
follows: If a trend is identified, then 1) how large an increase in sample size; or 2) how
large an increase in exposure time is recommended to have at least 80 percent power to
identify a statistically significant improvement?

Research Hypothesis

The hypothesis for this study is, “Utilizing the tools provided with both
commercially available ACO software and workplace wellness program structure, the
cost associated with managing the health care of individuals diagnosed with diabetes will
be reduced.”
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REVIEW OF THE LITERATURE

Diabetes the Disease

Diabetes is defined as, “a group of metabolic diseases characterized by
hyperglycemia resulting from defects in insulin secretion, insulin action, or both.”
(Diabetes Care, 2014) To better understand the disease, the following provides
information on the background of diabetes, diagnosing diabetes, health conditions that
increase the likelihood of diabetes, and historic trend of diabetes in the United States.

Background of Diabetes

The development of diabetes is based on two possible pathogenic processes, the
dysfunction of the pancreas resulting in inadequate production of insulin or the abnormal
insulin action by target tissues impacting one or more points in complex hormone action
pathways. While both paths frequently coexist in the same patient, it is difficult to
determine if the lack of insulin secretion or the inadequate insulin action is the direct
cause of the disease. These two predominant pathogenic processes are categorized as
Type 1 and Type 2 diabetes. Type 1 diabetes is specific to the dysfunction of the pancreas
preventing appropriate secretion of insulin. Type 2 diabetes is related to the abnormal
insulin action by target tissues. There are other specific types of diabetes but the majority
of diabetes is classified as either Type 1 or 2.
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Symptoms of diabetes are polyuria, polydipsia, weight loss, polyphagia, and
blurred vision. Diabetes can cause impaired growth, increased types of infections, and the
potentially fatal conditions of ketoacidosis or nonketotic hyperosmolar syndrome. While
both Type 1 and Type 2 diabetes present with similar symptoms, it is important to
understand that Type 1 diabetes can be diagnosed via serological evidence that detects
the inflammatory autoimmune condition of the pancreas or by utilizing genetic marker
analysis but the abnormal insulin reaction of tissues associated with Type 2 diabetes may
exist for a long period of time before presenting with clinical symptoms. Type 2 diabetes
can be diagnosed by measuring plasma glucose after a fasting period or by A1C
(Diabetes Care, 2014). The pathologic response of both Type 1 and Type 2 diabetes is
hyperglycemia, high blood sugar, which can exist in two different categories. The first
category, prediabetes, consists of impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG). Prediabetes is the result of having elevated blood glucose levels but not to
the level of being diagnosed with diabetes (Mayo Clinic, 2014). Prediabetes can lead to
diabetes but can also be corrected if detected early and proper lifestyle changes of
managing weight and participating in regular exercise are implemented. The second
category of hyperglycemia is diabetes. Obtaining the appropriate management of blood
glucose levels in conjunction with diabetes ranged from non-insulin therapy to insulin
dependency to sustain life (Figure 1).
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Figure 1: Disorders of Glycemia: Etiologic Types and Stages
Normoglycemia

Hyperglycemia

Stages
Normal Glucose
Regulation

Types

IGT
or
IGF

Diabetes
Not insulin
Requiring

Insulin for
Control

Insulin for
Survival

Type 1*
Type 2
Other Specific Types**

Gestational Diabetes**
*Patients presenting with ketoacidosis may return to Normoglycemia. **In rare cases patient may require
insulin for survival (Diabetes Care, 2014).

As stated previously, there are multiple types of diabetes with Type 1 and 2 being
predominant. Type 1 diabetes accounts for 5-10% of individuals with diabetes and is
historically known as insulin dependent diabetes or juvenile-onset diabetes. The specific
cause of Type 1 diabetes is the result of cellular-mediated destruction of the β-cells of the
pancreas reducing the secretion of insulin by the pancreas (Diabetes Care, 2014). Type 2
diabetes accounts for 90-95% of individuals with diabetes and is previously described as
the non-insulin dependent diabetes. Type 2 diabetes is directly related to an individual
developing insulin resistance or insulin deficiency (Diabetes Care, 2014). The other types
of diabetes (Table 1) consist of genetic abnormalities, diseases of the exocrine pancreas,
endocrinopathies, drug or chemical induced, infections, and gestational diabetes
(Diabetes Care, 2014).
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Table 1: Etiologic Classification of Diabetes (Diabetes Care, 2014)
I.

II.
III.

Type 1 diabetes (β-cell destruction)
A. Immune mediated
B. Idiopathic
Type 2 diabetes (insulin resistance)
Other specific types
a. Genetic defects of β-cell function
i. MODY 3 (Chromosome 12, HNF-1α)
ii. MODY 1 (Chromosome 20, HNF-4α)
iii. MODY 2 (Chromosome 7, glucokinase)
iv. Other very rare forms of MODY (e.g., MODY 4: Chromosome 13, insulin promoter
factor-1; MODY 6: Chromosome 2 NeuroD1; MODY 7: Chromosome 9, carboxyl
ester lipase)
v. Transient neonatal diabetes (most commonly ZAC/HYAMI imprinting defect on
6q24)
vi. Permanent neonatal diabetes (most commonly KCNJ11 gene encoding Kir6.2 subunit
of β-cell K ATP channel)
vii. Mitochondrial DNA
viii. Others
b. Genetic defects in insulin action
i. Type A insulin resistance
ii. Leprechaunism
iii. Rabson-Mendenhall syndrome
iv. Lipoatrophic diabetes
v. Others
c. Diseases of the exocrine pancreas
i. Pancreatitis
ii. Trauma/pancreatectomy
iii. Neoplasia
iv. Cystic fibrosis
v. Hemochromatosis
vi. Fibrocalculous pancreatopathy
vii. Others
d. Endocrinopathies
i. Acromegaly
ii. Cushing’s syndrome
iii. Glucagonoma
iv. Pheochromocytoma
v. Hyperthyroidism
vi. Somatostatinoma
vii. Aldosteronoma
viii. Others
e. Drug or chemical induced
i. Vacor
ii. Pentamidine
iii. Nicotinic acid
iv. Glucocorticoids
v. Thyroid hormone
vi. Diazoxide
vii. Β-Adrenergic agonists
viii. Thiazides
ix. Dilantin
x. γ-Interferon
xi. Others
f. Infections
i. Congenital rubella
ii. Cytomegalovirus
iii. Others
g. Uncommon forms of immune-mediated diabetes
i. Stiff-man syndrome
ii. Anti-insulin receptor antibodies
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iii. Others
Other genetic syndromes sometimes associated with diabetes
i. Down syndrome
ii. Klinefelter syndrome
iii. Turner syndrome
iv. Wolfram syndrome
v. Friedreich ataxia
vi. Hunington chorea
vii. Laurence-Moon-Biedl syndrome
viii. Myotonic dystrophy
ix. Porphyria
x. Prader-Willi syndrome
xi. Others
Gestational diabetes
h.

IV.

Diagnosing Diabetes

Diabetes has a long term impact on the eyes, kidneys, nerves, heart, and blood
vessels with the specific long term complications including: retinopathy that could lead to
the loss of vision; renal failure as a result of nephropathy; peripheral neuropathy with the
additional complications of foot ulcers, amputations, and Charcot joints; and autonomic
neuropathy resulting in gastrointestinal, genitourinary, cardiovascular symptoms, and
sexual dysfunction (Diabetes Care, 2014). Individuals diagnosed with diabetes could also
experience increased rates of atherosclerotic cardiovascular disease, cerebrovascular
disease, and peripheral arterial disease with specific comorbidities of hypertension and
abnormal lipoprotein metabolism (Diabetes Care, 2014).

Prior to 1997, a diagnosis of diabetes was based on either, fasting plasma glucose
(FPG) greater than 140 mg/dL (7.8 mmol/L) or an oral glucose tolerance test (OGTT)
that demonstrates an increase in blood glucose greater than 200 mg/dL. The Expert
Committee on Diagnosis and Classification of Diabetes Mellitus issued two reports, one
9

in 1997 and a follow up report in 2003 that identified a gap in the diagnosis values that
excluded individuals having glucose levels that are considered above normal ranges but
not high enough to meet the diagnosis criteria for diabetes (Expert Committee on the
Diagnosis and Classification of Diabetes Mellitus, 1997 and Genuth, Alberti, Bennett, et
al., 2003). Based on the work of the expert committee, the individuals with glucose levels
above the normal range but below established diabetes diagnosis ranges were classified
as having impaired fasting glucose (IFG), which is defined by FPG levels of 100 mg/dL
(5.6 mmol/L) to 139 mg/dL (6.9 mmol/L), or impaired glucose tolerance (IGT) with 2-h
values in the OGTT ranging from 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L).

In 2009, the Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus recommended the use of A1C to diagnose diabetes (International Expert
Committee, 2009). A1C is a minor component of hemoglobin to which glucose is bound.
A1C levels depend on the blood glucose concentration: The higher the glucose
concentration in blood, the higher the level of A1C. (MedicineNet, 2014) To further
support the use of A1C to diagnose diabetes, observational studies have provided
evidence of a strong correlation between retinopathy and A1C (van Leiden H.A., Dekker
J.M., Moll A.C., 2003 and Tapp R.J., Tikellis G., Wong T.Y., Harper C., Zimmet P.Z.,
Shaw J.E., 2008). In addition to observational studies, the correlation between A1C levels
and associated complications related to diabetes has been demonstrated in controlled
clinical trials for both type 1 (DCCT Research Group, 1995) and type 2 (Stratton, et al.,
2000) diabetes. As part of the Expert Committee’s work, an A1C level great than 6.5 was
identified as the appropriate diagnosis level when comparing the correlation between
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patients with retinopathy and an elevated A1C. At the time of the initial A1C
recommendation, the Expert Committee noted that the individuals above the normal
range but below the diagnostic indicator for diabetes (6.0 - 6.5) were at significant risk of
developing diabetes but the range failed to identify a substantial number of patients with
IFG and/or IGT (Diabetes Care, 2014). Subsequent research did determine that a FPG of
110 mg/dL (6.1 mmol/L) corresponds to an A1C of 5.6 and a FPG of 100 mg/dL
corresponds to an A1C of 5.4 (Diabetes Care, 2014) providing evidence of the A1C
ranges that supports the diagnosis of IFG utilizing A1C.

Individuals that are identified to have IFG or IGT are considered to have prediabetes. The relevance of this diagnosis is anyone with IFG or IGT have a relatively
high risk of developing diabetes in the future but implementing lifestyle changes such as
increasing physical activity, reducing body weight by 5 – 10%, and utilizing certain
pharmacological agents has demonstrated the delay or prevention of developing diabetes
in people with IGT (Diabetes Care, 2014). Research by the Diabetes Prevention Program
provides evidence that preventive interventions are effective for individuals with a mean
A1C of above and below 5.9 (Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al.,
2002). In addition, a systematic review of 44,203 individuals showed those with an A1C
of 5.5 - 6.0 had a 9% to 25% risk of developing diabetes over a 5-year period and those
with an A1C of 6.0 - 6.5 had a 20% to 25% over a 5-year period (Zhang, X., Gregg, E.
W., Williamson, D. F., et al., 2010).
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Prevalence of Diabetes

In 2012, 29.1 million Americans had diabetes (Centers for Disease Control and
Prevention, 2014). This is an increase of 3.3 million since the 2010 reporting period. Of
the approximately 29 million Americans diagnosed with diabetes, 21 million were
clinically diagnosed and the remaining individuals were identified as undiagnosed. In
addition to the 29.1 million Americans that had diabetes, there were an additional 86
million Americans over the age of twenty that had prediabetes in 2012 compared to 79
million in 2010 (Statistics About Diabetes, 2014). The youth statistic, those individuals
under twenty years old, identified roughly 280,000 Americans compared to 23,525 youth
in 2008-2009 (Statistics About Diabetes, 2014). Of the over 23,000 individuals under
twenty years old with diabetes in the 2008-2009 report, 5,089 were diagnosed with type 2
diabetes.

Further dissection of the 29.1 million adult Americans living with diabetes in
2012, specifically percentage by age, shows that individuals sixty-five years or older
account for 25.9% of the 29.1 million while individuals forty-five to sixty-six years old
and twenty to forty-four years old are 16.2% and 4.1%, respectively. Evaluation by sex
indicates that more men (13.6%) than women (11.2%) are living with diabetes (Centers
for Disease Control and Prevention, 2014). Examination based on race and ethnicity
yields the following composition among individuals diagnosed with diabetes: 7.6% of
non-Hispanic whites, 9.0% of Asian Americans 9.0%, 12.8% of Hispanics, 13.2% of
non-Hispanic blacks, and 15.9% of American Indians/Alaskan Natives (Statistics About
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Diabetes, 2014). Asian American adult diabetes rates are further segmented into 4.4% for
Chinese, 11.3% for Filipinos, 13.0% for Asian Indians, and 8.8% for other Asian
Americans. Similarly, Hispanic adults are broken down by 8.5% for Central and South
Americans, 9.3% for Cubans, 13.9% for Mexican Americans, and 14.8% for Puerto
Ricans (Statistics About Diabetes, 2014).

Comorbidities Associated with Diabetes

Based on data from 2010, diabetes is the seventh leading cause of death in the
United States as it was listed as the underlying cause of death on 69,071 death certificates
(Heron, 2013). It is thought that diabetes as a cause of death could be unreported as
studies have shown that only 35% to 40% of people with diabetes had diabetes listed on
their death certificate and only 10% to 15% had diabetes listed as the underlying cause of
death (Statistics About Diabetes, 2014).

As mentioned previously, diabetes can increase the risk of serious complications
such as heart disease and stroke, blindness, kidney failure, and lower-limb amputation.
Individuals with diabetes can also experience microvascular disease such as retinopathy
that could lead to the loss of vision; renal failure as a result of nephropathy; peripheral
neuropathy and autonomic neuropathy (Diabetes Care, 2014). Early diagnosis of diabetes
with proper glucose management and preventative health exams can reduce the risk or
further development of these complications. Failure to properly manage diabetes resulted
in 282,000 emergency room visits in 2011 that had hypoglycemia as the first diagnosis
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and diabetes listed as an additional diagnosis. In addition, 175,000 emergency room visits
in 2011 were associated with a hyperglycemic crisis such as, diabetic ketoacidosis and
hyperglycemic hyperosmolar state, as the first diagnosis. Data from 2009 to 2012
indicated that 71% of individuals diagnosed with diabetes had a blood pressure equal to
or above 140/90 millimeters of mercury or managed their blood pressure with
prescription medications. Data from the same timeframe also showed that 65% of adults
diagnosed with diabetes had increased LDL cholesterol levels or were using cholesterollowering medications (Centers for Disease Control and Prevention, 2014). Adults with
diabetes were 1.7 times more likely to die from cardiovascular disease from 2003 to
2006. During 2010, diabetics were 1.8 and 1.5 times more likely to be hospitalized for a
heart attack and stroke, respectively. From 2005 to 2008, 4.2 million diabetics, forty
years or older, were diagnosed with retinopathy or damage to small blood vessels in the
retina that could result in vision loss. During this same time period, 665,000 adults with
diabetes from the same age demographic suffered from advanced diabetic retinopathy
that could lead to severe vision loss (Centers for Disease Control and Prevention, 2014).
In 2011, 44% of new nephropathy or renal failure diagnoses listed diabetes as the primary
cause. Data from 2011 also showed that 49,677 diabetics of all ages began treatment for
renal failure and 228,924 individuals with renal failure, as a result of diabetes, were
living on chronic dialysis or with a kidney transplant. Diabetics twenty years or older
were about 60% of the non-traumatic lower-limb amputations in 2010. This percentage
was equal to roughly 73,000 non-traumatic amputations (Centers for Disease Control and
Prevention, 2014).
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Historic Trend of Diabetes in the United States

Over the last several decades, there has been a significant increase in diabetes
diagnosis. The Centers for Disease Control reports a 2.8% increase in diagnosed diabetes
among U.S. Adults (Figure 2). Further research based on NHANES (National Health and
Nutrition Examination Survey) data demonstrates a 3.8% increase in the prevalence of
diabetes from 1988 to 2010. Specifically, the prevalence of diabetes was reported as
follows; 5.5% with 4.6% diagnosed and 0.9% undiagnosed from 1988 - 1994, 7.7% with
6.4% diagnosed and 1.3% undiagnosed from 1999 - 2004, and 9.3% with 8.3% diagnosed
and 1.0% undiagnosed. The rate of prediabetes based on A1C levels of NHANES was
5.8% in 1988 – 1994, 11.9% in 1999 – 2004, and 12.4% in 2005 – 2010 (Selvin,
Parrinello, Sacks, and Coresh, 2014).

80.00%

9.0%+

60.00%

7.5% - 8.9%
6.0% - 7.4%

40.00%

4.5% - 5.9%
<4.5%
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Figure 2: Age-Adjusted Prevalance of Diagnosed Diabetes
Among U.S. Adults

Although a 3.8% increase in diabetes was reported over the period of 1988 –
2004, the rate of undiagnosed diabetes remained relatively consistent. This demonstrates
that while diabetes as a disease is becoming more prevalent in the United States, the
diagnosis of diabetics is staying relatively consistent. When evaluating the prevalence of
diagnosed diabetes among minorities compared with the previously reported data with
whites, non-Hispanic blacks was 15.4%, Mexican Americans was 11.6%, and whites was
8.6%. As expected the ethnic minority groups also had a higher prevalence of
undiagnosed diabetes. While diabetes is not directly related to obesity, it is important to
note that the mean BMI of the United States undiagnosed diabetes population increased
from 21.2% in 1988 – 1994 to 32.4% in 2005 – 2010 (Selvin, Parrinello, Sacks, and
Coresh, 2014).
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Health Care Costs Associated with Diabetes

As stated previously, diabetes is a very complex disease that can be caused by
many factors and a wide range of comorbidities. The following section will provide an
overview of proper disease management, the financial impact on personal health care
expense and quality of life, and financial impact to the health care industry.

Proper Disease Management

Disease management has evolved over many decades. In 1997, Ellrodt, et al.
defined disease management as, “programs that used a systematic approach to care and
included more than one intervention component.” Expansion of the idea of disease
management has further developed the definition as the following, “Disease management
is a system of coordinated health care interventions and communications for populations
with conditions in which patient self-care efforts are significant. Disease management
supports the physician or practitioner/patient relationship and plan of care, emphasizes
prevention of exacerbations and complications utilizing evidence-based practice
guidelines and patient empowerment strategies, and evaluates clinical, humanistic, and
economic outcomes on an ongoing basis with the goal of improving overall health.”
(Congressional Budget Office, 2004)
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As stated in the definition of disease management, patient self-care effort is a
significant component of disease management. Specifically, proper disease management
requires a patient to engage in activities and life style changes that prevent further
exacerbation and complications of diabetes. Recommended diabetic patient self-care
behaviors include proper nutrition therapy, exercise, glycemic control, and management
of dyslipidemia.

Proper nutrition therapy is focused on maintaining blood-glucose levels within
normal range, proper lipid and lipoprotein profile management, normal blood pressure
levels, and proper nutrition intake to prevent and treat obesity, dyslipidemia,
cardiovascular disease, hypertension, and nephropathy (Brantle, et al., 2006). The
specific goals and recommending body for each of the nutritional therapies are listed in
Table 2. A key component of maintaining normal glucose levels is the monitoring of total
carbohydrate intake in reference to postprandial glucose levels. The ability for a diabetic
to process glucose is related to the amount of insulin available in the body. The variation
of low and high glycemic index foods as well as the amount and type of carbohydrates
consumed during a meal, determines the amount of insulin needed to return to a normal
postprandial glucose level.

Exact exercise guidelines for a diabetic, specifically aerobic and resistance
exercise, tend to follow the general guidelines of 150 minutes of moderate-intensity or 90
minutes of vigorous exercise per week to achieve glycemic control as well as reduce the
risk of coronary heart disease (Zimmerman, 2013). Due to the complications associated
with diabetes, as it relates to loss of sensation in the feet, the types of exercise should be
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evaluated appropriately. The risk of coronary heart disease associated with diabetes is
also an area of concern. Individuals should be screened and cleared by their health care
provider prior to beginning any exercise programs.

Table 2: Goals for Risk Factor Management in Patients with Diabetes (Zimmerman,
2013)
Risk Factor
Goal of Therapy
Recommending Body
Cigarette smoking

Complete cessation

ADA

Blood pressure

<130/85 mm Hg
<130/80 mm Hg
<100 mg/dL

JNC VI (NHLBI)
ADA
ATP III (NHLBI), ADA

Non-HDL cholesterol
level <130 mg/dL
Raise HDL (no set goal)

ATP III (NHLBI)

Low-dose aspirin therapy
(patients with CHD and
other risk factors)
HbA1c <7%

ADA

Decrease BMI

OEI (NHLBI)

Exercise prescription
depending on patient’s
status

ADA

LDL cholesterol level
Triglyceride level
200-499 mg/dL
HDL cholesterol
level <40 mg/dL
Prothrombotic state

Glucose
Overweight and obesity
(BMI ≥ 25 kg/m2)
Physical inactivity
Adverse nutrition

ATP III (NHLBI)

ADA

ADA, AHA, and NHLBI’s
ATP III, OEI, and JNC VI

ADA, American Diabetes Association; AHA, American Heart Association; ATP III, National Cholesterol Education Program
Adult Treatment Panel III; BMI, body mass index; CHD, coronary heart disease; HDL, high-density lipoprotein; JNC VI,
Sixth Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure; LDL, lowdensity lipoprotein; NHLBI, National Heart, Lung, and Blood Institute; OEI, Obesity Education Initiative Expert Panel on
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. (Zimmerman, 2013)

Glycemic control, when administered properly, has the ability to reduce a
diabetic’s A1C level. Successful glycemic management is based on an intensive
management of insulin, blood glucose monitoring, and regular evaluations by a health
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care provider. The Diabetes Control and Complication Trial (DCCT Research Group,
1993) is a well-known study that demonstrated a difference between intensive and
conventional glycemic treatment. The intensive glycemic treatment consisted of
randomly selected study participants receiving insulin via an insulin pump or insulin
injection three or more times per day as determined by self-monitoring of blood glucose
three or four times per day. A health care provider saw the participants at least once a
month. The conventional glycemic treatment consisted of randomly selected study
participants receiving only two injections of insulin per day based on the monitoring of
blood glucose no more than twice a day and were seen by a health provider every two or
three months. The study resulted in an average A1C of 7.2% for the intensive treatment
group and 9.1% for the conventional treatment group over a 6.5-year period (DCCT
Research Group, 1993).

Management of dyslipidemia also contributes to proper disease management of
diabetes. Specific guidelines were developed as a result of lipid-lowering trials that
included diabetic patients and were confirmed in additional trials (Zimmerman, 2013).
The guidelines are as follows: (1) Diabetic’s should have an LDL cholesterol level of
<100 mg/dL, (2) If LDL cholesterol level is <100 mg/dL and triglycerides levels are
elevated then HDL cholesterol should be <130 mg/dL, (3) Diabetic patients that have
suffered a myocardial infarction should have an LDL cholesterol level of <70 mg/dL, and
(4) Patients with an LDL cholesterol level, without medication of <100 mg/dL, should
have a treatment plan of 30% reduction in LDL cholesterol level.
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In addition to the self-patient care requirements, individuals with diabetes need to
establish and maintain a relationship with health care professionals that can provide
screenings and evaluations specific to the progression of diabetes. Diabetic’s should be
evaluated for: diabetic retinopathy to monitor eye health and establish a plan of treatment
to avoid vision loss, diabetic nephropathy to maintain kidney health, peripheral
neuropathy in the feet as a predecessor to the potential development of foot ulcers, and
ischemic coronary disease as many patients with diabetes do not experience the
associated chest pain with exertion (Zimmerman, 2013).

The Financial Impact on Personal Health Care Expense and Quality of Life

In 2007, the estimated economic burden from elevated glucose levels (diagnosed
and undiagnosed diabetes, prediabetes, and gestational diabetes (GDM)) was reported to
be $218 billion. This amount consisted of $153 billion in increased medical costs and $65
billion representing reduced productivity (Dall, Zhang, Chen, Quick, Yang, and Fogli,
2010). More recent research from the American Diabetes Association estimated the total
estimated cost of diagnosed diabetes in 2012 as $245 billion, which included $176 billion
in direct medical costs and $69 billion in reduced productivity (American Diabetes
Association, 2013). The 2013 study by the American Diabetes Association further
segregated the estimated $176 billion in direct medical costs by listing the contributing
percentages as follows: hospital inpatient care (43%), prescription medications to treat
the complications of diabetes (18%), anti-diabetic agents and diabetes supplies (12%),
physician office visits (9%), and nursing/residential facility stays (8%). Additional
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research reports an increase of 48% from the burden identified in 2007. Dall et al, (2014)
estimates the economic burden of elevated glucose levels for 2012 to be in excess of
$322 billion consisting of $244 billion in excess medical costs and $78 billion in reduced
productivity.

To evaluate the financial impact for individuals with diabetes, it is important to
assess the number of people with diabetes for 2012. The CDC reports during the 2012
time period that approximately 29.1 million people with diagnosed diabetes, 8.1 million
with undiagnosed diabetes and 86 million prediabetic adults in the United States (Centers
for Disease Control and Prevention, 2014). The American Diabetes Association identifies
a 6% increase in diagnosed diabetics compared to the CDC with an estimated 22.3
million individuals in 2012 (American Diabetes Association, 2013). The difference
between the CDC and the American Diabetes Association is based on the prevalence
calculations utilized and the adjustment for the prevalence of diabetes among residence in
nursing homes.

Utilizing the population statistics provided the CDC and the American Diabetes
Association, the national cost of diabetes by specific category is reported as $244 billion
for diagnosed diabetes, $33 billion for undiagnosed diabetes, $44 billion for prediabetes,
and $1.3 billion for GDM. This information, as well as a detailed individual cost by age
is presented in Table 3. From the period of 2007 and 2012 the financial burden of
diabetes grew by 40% for diagnosed diabetes, 82% for undiagnosed diabetes, 74% for
prediabetes, and 103% for GDM (Dall, et al., 2014).
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Table 3: U.S. Economic Costs Associated with Diabetes and Prediabetes, by Age Group,
2012 (Dall, et al., 2014)

Assessing the quality of life impact attributed to diabetes is based on several
factors. As mentioned earlier, loss of productivity is a key impact area attributed to
diabetes. Productivity can be measured based on absenteeism or presenteeism from work,
inability to work, productivity reductions for those outside of the workforce, and early
mortality. Absenteeism is defined as the number of workdays missed due to poor health.
It has been reported that workers with diabetes average three more missed days at work
than individuals without. Presenteeism is defined as reduced work productivity while at
work and is reported at a greater rate than those without diabetes, ranging from 1.8% to
38% (American Diabetes Association, 2013). Inability to work is related to the impact of
23

long-term disability as a direct result of diabetes. The CDC estimates that approximately
65,700 lower-limb amputations are performed each year on diabetics (CDC, 2011). As
stated previously, diabetes has the potential to impact vision and renal functionality in
addition to lower limb amputations. All of which would have a significant impact on
quality of life. Productivity reductions for those outside of the workforce is a measure of
reduced time spent providing childcare, household activities, and being active in the
community. Premature death as, it relates to diabetes, is measured by determining the
number of premature deaths that are attributed to diabetes and calculate the expected
future earnings (American Diabetes Association, 2013). Table 4 lists the specific data
collected for diabetics in the United States, 2012.

Table 4: Quality of Life Impact of Diabetes in the United States, 2012 (American
Diabetes Association, 2013).
Quality of Life Component
Absenteeism
Presenteeism
Inability to Work Due to Disability
Reduced Productivity Outside of
Workforce
Mortality

Productivity Loss
25 million days
113 million days
130 million days
20 million days
246,000 deaths

What is not included in the data of Table 4 is the more subjective impact to
quality of life. Individuals with diabetes have an increased risk of diabetic retinopathy,
renal failure and lower limb medical issues that could consist of peripheral neuropathy,
ulcers, and possibly amputations. Diabetes is also considered the leading cause of
blindness among individuals in the twenty to seventy-four year old age range (CDC,
2013). These health concerns will cause lifestyle modifications for the diabetic as well as
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impact the quality of life for friends or family members serving as primary care
providers.

Financial Impact to the Health Care Industry

When considering the financial impact of diabetes, it is also important to assess
the impact the disease has on the health care industry. Specifically, the American
Diabetes Association (2013) has provided 2012 data (Table 5) that demonstrates how
diabetes is attributed to health resource utilization. In the U.S. in 2012, roughly 25.7% of
hospital inpatient days are incurred by people with diabetes. That accounts for 43.1
million of the 168.0 total inpatient days of which 26.4 million are attributed to diabetes.
Of the 3.6 billion outpatients care visits reported for 2012, 942.3 million are incurred by
people with diabetes and 487.9 million are directly attributed to diabetes care. Further
evaluation of the 2012 data shows that 8.3% of all outpatient visits, 5.7% of all
emergency department visits, and 11.8% of medication prescriptions are associated with
some type of diabetes care. In comparison with 2007 data, it is reported that use of
medication attributed to diabetes has more than doubled (American Diabetes Association,
2013).

Analyzing health resource data utilization attributed to diabetes by medical
condition and type of service, specifically diabetes, chronic complications, and general
medical conditions demonstrates that of the 85.7 million diagnosis codes recorded for
physician office visits in 2012 33% were specific to diabetes, 34% were from chronic
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complications of diabetes (neurological, peripheral vascular, cardiovascular, renal,
metabolic, ophthalmic, and others related to diabetes), and 33% were for general medical
conditions. Similarly, of the 7.8 million outpatient diagnosis codes reports for 2012, 39%
were diabetes, 33% were for chronic complications of diabetes, and 28% were general
medical (American Association of Diabetes, 2013).

Table 5: Health Resource Use in the United States by Diabetes Status and Cost
Component, 2012 (in millions of units) (American Diabetes Association, 2013)

Health care costs for 2012, based on the total health care expenditures for people
with diabetes minus the projected level of expenditures that would have occurred for
those people in the absence of diabetes, were projected to be over $1.3 trillion, of which,
$306 billion were incurred by individuals with diabetes and $176 billion is attributed to
the cost of diabetes. That equates to more than one in every ten health care dollars being
attributed to diabetes (American Diabetes Association, 2013). The greatest contributor to
the overall health care expenditures attributed to diabetes is from higher rates of
hospitalization admission and longer lengths of stay. It is estimated that $124 billion of
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the projected $475 billion in hospital inpatient care is incurred by people with diabetes
and $76 billion in national medical cost is directly related to diabetes. Similar analysis of
medication expense shows that $77 billion of the projected $286 billion national
medication expense is incurred by individuals with diabetes and $50 billion is attributed
to their diabetes.

While diabetes impacts finances and quality of life for individuals and the
resources of the health care system, it ultimately impacts all of society increasing
insurance premiums and taxes, reduces earnings, and reduces the standard of living.
Specifically, for the 314 million Americans in 2012, the financial burden of diabetes
represents a hidden tax averaging over $1,000 per person in the form of higher medical
insurance cost and reduced productivity (Dall, et al., 2014).

Wellness Programs

In recent years, many organizations have identified the need to introduce
workplace wellness programs to improve the overall health of employees, positively
impacting employee satisfaction, and reducing the cost to provide health care insurance
as a workplace benefit.

The following section explains the difference between disease management and
workplace wellness programs, characteristics of a successful workplace wellness
program, and the financial and quality improvements of workplace wellness programs.
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Disease Management and Workplace Wellness Programs

As mentioned previously, “Disease management is a system of coordinated health
care interventions and communications for populations with conditions in which patient
self-care efforts are significant. Disease management supports the physician or
practitioner/patient relationship and plan of care, emphasizes prevention of exacerbations
and complications utilizing evidence-based practice guidelines and patient empowerment
strategies, and evaluates clinical, humanistic, and economic outcomes on an ongoing
basis with the goal of improving overall health.” (Congressional Budget Office, 2004)
“Disease management programs are comprised of the following six components: (1)
population identification processes, (2) evidence-based practice guidelines, (3)
collaborative practice models to include physician and support-service providers, (4)
patient self-management education (may include primary prevention, behavior
modification programs, and compliances/surveillance), (5) process and outcomes
measurement, evaluation, and management, and (6) routine reporting/feedback loop (may
include communication with patient, physician, health plan and ancillary providers, and
practice profiling). Full-service disease management programs must include all six
components. Programs consisting of fewer components are disease management support
services.” (Congressional Budget Office, 2004).

Wellness programs, specifically workplace wellness programs, differ from disease
management programs based on the fact that workplace programs are, “a coordinated and
comprehensive set of health promotion and protection strategies implemented at the
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worksite that includes programs, policies, benefits, environmental supports, and links to
the surrounding community designed to encourage that health and safety of all
employees.” (CDC, 2015) Workplace wellness programs address multiple risk factors
and health conditions simultaneously facilitating individual employee behavior change,
organizational culture, and worksite environment. Per the CDC (2015), workplace
wellness programs can be divided into the following four major categories: (1) Healthrelated programs defined as opportunities available to employees at the workplace or
through outside organizations to begin, change, or maintain health behaviors, (2) Healthrelated policies defined as formal or informal written statements that are designed to
protect or promote employee health, affecting large group of employees at the same time,
(3) Health benefits or a part of an overall compensation package including health
insurance coverage and other services or discounts regarding health, and (4)
Environmental supports referring to the physical factors at and nearby the workplace that
help protect and enhance employee health. By utilizing these categories individually or in
combination will provide the framework to further assist employees to improve current
health or identify specific health risks that may require more specific disease
management.

Characteristics of Successful Workplace Wellness Program

In reviewing the literature related to workplace wellness programs, most authors
reference the Live for Life (Henke, Goetzel, McHugh, Isaac, 2011) program that was
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initiated in 1979 and has been used as the basis for most workplace wellness programs
that followed. As reported by Phillips (2009), Johnson & Johnson’s Live for Life
program has been associated with decreased medical spending and employee health risk
factors and an increased return of investment for the organization since 1980. Based on
the Live for Life program and additional workplace wellness programs modeled after the
program, six specific characteristics are associated with successful workplace wellness
programs. First, corporate culture must introduce and maintain the wellness program as a
benefit to the health of the individual participant and not primarily a cost savings
measure. Second, employees and corporate leadership are dedicated to the wellness
program and overall health improvement. Third, the program support is attributed to
having participation-friendly corporate policies and physical environment. Fourth, the
wellness program is not static but adaptive to the changing needs of the participants.
Fifth, community health organizations are engaged in the wellness program and provide
support, education, and treatment. Sixth, technology is utilized to complete health
assessment and wellness education (Kaspin, Gorman, and Miller, 2013). In addition to
the six characteristics associated with successful workplace wellness programs, key
wellness interventions included are health risk assessments, lifestyle management
activities, and behavioral programs (Kaspin, Gorman, and Miller, 2013).

Health risk assessments are used to determine if individual employees may be at
risk for conditions such as cardiovascular disease or diabetes. Generally, health
assessments consist of biometric screenings to score specific risk factors such as
cholesterol, A1C, body mass index, blood pressure, and tobacco use. Questionnaires may
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be included in health risk assessments to evaluate behaviors that contribute to overall
health condition such as diet, exercise, sleep patterns, alcohol use. Through the health
assessment, it is possible to identify risk factors that can be addressed via lifestyle
management (Kaspin, Gorman, and Miller, 2013).

Lifestyle management consists of activities such as fitness programs and
competitions that engage employees in becoming more active. Lifestyle management can
also include educational programs that inform employees on health behaviors and
provide guidance on how to integrate the behaviors into daily routines. In addition to
fitness programs education sessions, some wellness programs may also offer health
coaches to assist with obtaining more directed success in becoming healthier (Kaspin,
Gorman, and Miller, 2013). Lifestyle management is a primary area of wellness programs
that incentives are utilized to promote involvement.

Behavioral health programs consist of behavior modification programs that assist
individuals with smoking cessation, drug and alcohol addictions, and psychological
council to address mental issues that are impacting a healthy lifestyle (Kaspin, Gorman,
and Miller, 2013).

In addition to offering the above-mentioned interventions, workplace wellness
programs can provide incentives to encourage participation in completing health risk
assessments, participation in lifestyle management programs, receiving preventative care
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and for continued improvement in risk factors. Examples of the incentives are financial
rewards, gift cards, vacations, prepaid gas cards, and electronics. Workplace wellness
programs may also include financial assistance to minimize the impact to employees that
are willing to improve health. This may include discounts on health insurance preventive
premiums, preventive care coverage, and medicines (Kaspin, Gorman, and Miller, 2013).

Financial and Quality Improvements of Workplace Wellness Programs

Most workplace wellness programs can demonstrate a return on investment and
overall quality improvements to support the value of initiating a program. Johnson &
Johnson’s Live for Life provided an annual savings of $225 per employee savings, which
equates to an $8.55 million annual savings (Henke, Goetzel, McHugh, and Isaac, 2011).
From 2002 to 2008, the Live for Life program was able to have a 3.7% lower than
average annual growth in medical costs compared to a comparison group made of
companies of similar size and in a similar industry (Kaspin, Gorman, and Miller, 2013).
The program, in 2009, had an annual average savings of $565 per employee savings
resulting in a return on investment ranging from 1.88 to 3.92 based on a conservative
program cost estimate of $300 per employee. A similar review of a wellness program
offered by Fairview Health Services reported that in 1999 the overall annual medical cost
per employee was $4640 in 1999. For the time period the 1999 cost per employee was
almost $1000 higher than the national healthcare averages. Each year of the program had
a cost savings per employee culminating in 2003 with a savings of $282 per employee. In
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2004 the average cost for health care per employee for Fairview Health Services was
$6511, which was $200 per employee below the national average for the industry
(Fairview, 2006). Naydeck reported in 2008 that the Highmark Health Tracks and Extra
Mile workplace wellness program participants had a $176.47 per employee lower health
care costs when compared to the nonparticipant group (Naydeck, Pearson, Ozminkowski,
Day, and Goetzel, 2008). Providence General Medical Center’s was able to reduce their
monthly medical claims by 24% and saved over $2 million over a six year period
(Providence, 2000).

In addition to evaluating overall health care cost savings, several studies reported
decreases in health insurance premiums (Kaspin, Gorman, and Miller, 2013). In 2007,
Cable reported that the Highsmith wellness program impacted health insurance premiums
by incurring a 4.6% premium increase over a five year period while health care costs for
United States employers increased 60% during the same period. A study completed by
the Oswald Company, reported that companies with workplace wellness programs had
insurance premiums $1030 per employees less than similar companies without wellness
initiatives (Sammer, 2006). Redstone’s workplace wellness program saw an 8% decrease
in health care premiums in the first year of the program (Hodge, 2006).

Indirect health care costs were also reported as a positive impact workplace
wellness programs (Kaspin, Gorman, and Miller, 2013). One study reported a decrease of
20% in workers compensation costs that had a wellness coach located at the facility for a
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year or longer. The same study also reported 75% fewer lost workdays annually for
locations that participated in wellness program activities (Abt, 2009). Both the
Providence and Highsmith workplace wellness programs resulted in a reduction of lost
work time by reporting a 37% annual reduction in sick time and a one third to one half
reduction in the annual absenteeism rate, respectively (Providence, 2000 and Cable,
2007).

The top four categories of health quality improvements reported across twenty
separate workplace wellness programs were, increased exercise level, health risk
reduction, smoking cessation, and decreased blood pressure (Kaspin, Gorman, and
Miller, 2013). Participants in Live for Life program offered by Johnson & Johnson
experienced decreased health related risks for high blood pressure (4.1% lower), high
cholesterol (0.3% lower), poor nutrition (6.7% lower), obesity (6.6%), physical inactivity
(0.7% lower), and tobacco use (10.6% lower) (Henke, Goetzel, McHugh, and Isaac,
2011). Highsmith employees in the high-risk category for cholesterol improved by 66%
and overall health measurements and blood pressure improved (Cable, 2007). Con-way
Freight’s workplace wellness program resulted in 831 employees losing a combine total
of 6,269 pounds, 170 employees quitting smoking, 669 employees reduced hypertensive
blood pressure levels, almost 1,470 employees successfully lowered blood pressure
through exercise and proper diet, and over 5,300 employees benefited from a total of
74,360 one-on-one coaching sessions (Con-way Inc., 2008).
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The Patient Protection and Affordable Care Act

The Patient Protection and Affordable Care Act was signed by President Barack
Obama, March 23, 2010 with the goal of improving access to affordable health care.
Initial analysis of the 906-page act estimated that 95% of all Americans would be
insured, providing insurance coverage to an additional 32 million citizens (Healthcare
Reform, 2011). The following analysis of the Patient Protection and Affordable Care Act,
outlines the: (1) policy options that lead to the final law, (2) identification of proponents
and opponents, and (3) the outcome for health care finance, delivery and quality.

Policy Options

Health care reform is a significant public policy debate that many presidents have
attempted to address during their time in office (Hartung, 2012). During the 2008 United
States presidential election, Senator Barak Obama, campaigned on the platform that the
cost of health care was a threat to the United States economy and that health care should
be a right for every American (Healthcare Reform, 2011). After winning the 2008 United
States presidential election, President Barak Obama challenged Congress to create a
health care reform bill based on eight principles (President’s Plan for Health Care, 2009):

1. Reduce long-term growth of health care costs for businesses and government
2. Protect families from bankruptcy or debt because of health care costs
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3. Guarantee choice of doctors and health plans
4. Invest in prevention and wellness
5. Improve patient safety and quality of care
6. Assure affordable, quality health coverage for all Americans
7. Maintain coverage when you change or lose your job
8. End barriers to coverage for people with pre-existing medical conditions.

In response to President Obama’s challenge the U.S. House of Representatives
approved the Affordable Health Care for America Act (HR 3962) with a vote of 220-215.
While House Democrats predominantly supported the bill, 39 Democrats voted against
the bill and only 1 Republican voted in favor of the bill (Clerk of the U.S. House of
Representatives, 2009). The estimated impact of the proposed bill was; (1) a cost of over
$1.1 trillion dollars, (2) provide coverage for 36 million uninsured Americans, (3) create
a government health insurance program, and (4) reduce the federal deficit by $118 billion
dollars over a nine-year period (Healthcare Reform, 2011).

The Senate approved Patient Protection and Affordable Care Act (HR 3590), in a
60-39 party-line vote in response to health care reform challenge from President Obama
(U.S. Senate Roll Call Votes, 2009). Interestingly, bill HR 3590 was originally passed in
the U.S. House of Representative as the Service Members House Ownership Tax Act of
2009, which modified the home buyer’s credit for members of the Armed Forces and
certain Federal Employees (Healthcare Reform, 2011). The original bill had nothing in
common with health care reform but was co-opted by the Senate, changing the existing
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language, to become the Patient Protection and Affordable Care Act. The Senate took this
approach because the Constitution requires all revenue-based bills to start in the House of
Representatives and the proposed Senate bill on healthcare reform involved revenue
(GovTrack, 2013). Senate Republicans argued that the bill was unconstitutional,
socialistic, and too costly and would increase the cost of health insurance for those
already insured. The estimated impact of the Patient Protection and Affordable Care Act
was; (1) a cost of $871 billion dollars, (2) provide coverage for 31 million uninsured
Americans, (3) would require the majority of Americans to have health insurance, and (4)
reduce the federal deficit by $138 billion dollars over a nine-year period (Healthcare
Reform, 2011). Figure 3, provides a detailed comparison of the House and Senate bills.

Figure 3: Comparison of the Patient Protection and Affordable Care Act (HR 3590) to
the Affordable Health Care for America Act (HR 3962) – December 24, 2009
SOURCE: Side-By-Side Comparison of Major Health Reform Proposals, Henry J. Kaiser Family Foundation (2009).

Similarities

Public Option

Individual Mandate

Both create Health
Insurance/Benefit Exchanges,
which governments may
administer, where individuals and
employers can purchase coverage.
Both have restrictions on coverage
for abortion beyond what is
permitted by federal law (to save
the life of the woman and in cases
of rape and incest).

Both require individuals to have
qualifying health coverage, and
both penalize those without
coverage, with exemptions for
religious objections and financial
hardship.
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Difference
HR 3962: Creates the Health
Insurance Exchange, where a
public insurance option is offered.
States may operate their own
Exchanges. Access to the
exchange is limited to all
individuals who do not already
have coverage through individual,
employer, or government
insurance.
HR 3590: Requires at least two
multi-state plans in each
Exchange, one of which must be a
non-profit. Access to the health
insurance exchanges is limited to
U.S. Citizens and legal
immigrants who are not
incarcerated.
HR 3962: Penalty is equal to 2.5%
of adjusted income up to the cost
of the average national premium
for coverage under a basic plan in
the Exchange, effective 2013.

Both assess penalties on employers
who do not offer health care
coverage to their employees.

Employer Mandate

Individual Subsidies

Employer Subsidies

Both offer subsidies to low- and
middle-income individuals and
families on a sliding scale up to
400% of the Federal Poverty Level.
Both allow individuals to seek
subsidies if their employer offers
health premiums above a threshold
percentage of income. Both limit
subsidies to U.S. citizens and legal
immigrants. Both restrict use of
subsidies for coverage of abortion
that goes beyond what is federally
permitted.
Both offer subsidies to employers
with less than 25 employees and
average annual wages of less than a
specific threshold. Both offer a
temporary reinsurance program for
employers providing health
insurance coverage to retirees over
the age of 55 that are not eligible of
Medicare. Both reinsurance
programs reimburse employers for
80% of retiree claims between
$15K-$90K, which will be used to
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HR 3590: Penalty is equal to
$750/year for individuals and up
to $2,250 for families. Penalty is
phased-in starting in 2014.
HR 3962: Penalty for not offering to
contribute at least 72.5% of
premium cost of coverage (65% for
families) is equal to 8% of payroll
for employers with payroll of $750k
or more; penalties are phased in for
employers with $500 - $750k,
exempt for employers with payroll
of less than $500k. Automatic
enrollment into lowest-cost plan for
all employees. Report on impact of
employer responsibility
requirements to consider whether an
employee hardship exemption is
appropriate due by 1/1/12.
HR 3590: No penalty is assessed for
employers with less than 50
employees/employers whose
employees do not receive insurance
exchange tax credit. Lesser of
$3,000 per employee receiving
coverage subsidy or $750 penalty
per full-time employee if at least
one employee receives coverage
subsidy in a business with 50+
employees. Fee of $400 for any fulltime employee on which a 30-60
day waiting period for coverage is
imposed and $600 for a 60-90 day
waiting period. Employers with
200+ employees automatically
enroll employees into health plans
(employees may opt out).
HR 3962: Employer premium
threshold is 12% of income.
Subsidies are effective January 1,
2013. Establishes sliding scale
limits on out-of-pocket spending.
HR 3590: Employer premium
threshold of 9.8% of income.
Subsidies are effective January 1,
2014.

HR 3962: Average annual wage
threshold is below $40K. Subsidy is
provided for no more than two
years. Offer 50% credit of premium
costs paid by employers who have
less than 10 employees or average
annual wages of less than $20K.
Effective 2013. Appropriates $10
billion for the reinsurance program.
HR 3590: Average annual wage
threshold is below $50K. Starts of
offering up to 35% credit for

lower the costs for enrollees in the
employer plan.

Financing Reform

Both make cuts to Medicare and
Medicaid payments. Impose fees
on medical device makers, collect
fines from individuals and
employers that do not obtain/offer
health care coverage, prohibit
reimbursement of non-prescribed
drugs through health savings
accounts, and increase tax on
health savings distributions that are
not used for qualified medical
expenses.

Private Insurance

Both establish a temporary highrisk pool to provide coverage to
individual with pre-existing
conditions that have not been
insured for at least six months
prior. Both prohibit private
insurance companies from denying
coverage or charging higher
premiums because of a person's
medical history. Both prohibit
lifetime limits on coverage. Both
would strip private insurance from
antitrust exemptions.

Regulation

Prevention/Wellness

Improvements to Health
System Performance

Both create task forces to develop,
update and disseminate evidencebased recommendations on the use
of clinical and community
prevention services and offer grants
to fund these efforts. Both cover
proven preventive services and
eliminates cost sharing for
preventive services in Medicare
and Medicaid. Both require chain
restaurants and food sold from
vending machines to disclose
nutritional content. Both offer
grants to employers for offering
wellness programs to its
employees.
Both support comparative
effectiveness research with
establishment of institutes; seek to
explore alternatives to medical
liability laws; create Independence
at Home demo program to provide
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employer’s premium costs paid if
employer contributes at least half of
the premium cost, phases in up to
50%. Full credit available to
employers with less than 10
employees and average annual
wages of less than $25K and phases
out as firm size and average wage
increases. Appropriates $5 billion
for the reinsurance program.
HR 3962: Income tax of 5.4% of
gross income on individuals making
$500K/couples making $1M
annually.
HR 3590: Excise tax on health plans
with value of $8,500 for individuals
and $23,000 for families. $2.3B
annual tax on pharmaceuticals, $2B
tax on medical device makers, $2B
on health insurance sector (increases
to $10B by 2017). 10% tax on
amount paid for indoor tanning
services.
HR 3962: Requires medical loss
ratio of no less than 85%. Children
up to 27 years old have access to
dependent coverage. Removes
anti-trust exemption for health
insurers and medical malpractice
insurers.
HR 3590: Requires medical loss
ratio of no less than 80% for
individual and small group
markets and 85% for all others.
Children up to 26 years old have
access to dependent coverage.
Prohibits waiting periods of
coverage of more than 90 days.
Limit deductibles for individuals
to $2k, $4k for families.
HR 3962: Grants available to
community health workers to
promote positive, healthy lifestyles
in underserved communities and
grants to plan and implement
programs to prevent obesity.
HR 3590: Requires qualified
health plans to provide coverage of
effective preventive services.

HR 3962: Strengthens financial
support to primary care providers;
enact studies on geographic
variation adjustments for Medicare
payments; conduct study on
Medicare payments for English

high-need Medicare patients with
primary care services in their home
and allow providers to share in
cost-savings associated with
reduced hospital admissions;
improve care coordination for
dually eligible; expand Medicaid
and CHIP Payment and Access
Commission to include adults;
establish best practices for health
care delivery; require disclosure of
financial relationships between
health entities, enhance collection
and reporting of data on race, sex,
primary language, and disability
status.
Both would expand Medicaid
eligibility and federal government
would pick up the cost of
expansion for at least two years,
eventually moving to a federalstate shared funding plan.

Expansion of Public
Programs

Cost Containment

Both simplify health insurance
administration by setting standards
for financial and administrative
transactions; reduce payments to
Medicare Advantage plans and
offer bonus payments for higherquality plans; reduce payments to
Disproportionate Share Hospitals;
create innovation centers to test
more efficient service delivery
models; reduce Medicare payments
to hospitals for preventable
readmissions, prohibit federal
payments to state for services
related to health care acquired
conditions; increase Medicaid drug
rebate percentage to 23.1% (from
15.1%); authorize FDA to approve
generic versions of drugs.
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language assistance. Increases
Medicaid payments for primary care
(cont.) providers to 100% of
Medicare rates.
HR 3590: Pays hospitals based on
performance on quality measures;
establishes pilot program for
bundled payments.

HR 3962: Medicaid expanded to
all individuals under the age of 65
with incomes up to 150% of the
Federal Poverty Level. Federal
government would pick up full
cost of expansion from 2013 2014. Afterwards, federal
government would pay 91% and
states pick up the remaining 9%.
Repeals Children’s Health
Insurance Program (CHIP) and
requires enrollees to instead enroll
in the Exchange. If children have
below 150% of the Federal
Poverty Level, they may remain
enrolled in Medicaid.
HR 3590: Medicaid expanded to
all individuals under the age of 65
with incomes up to 133% of the
Federal Poverty Level. Federal
government would fully finance
expansion for three years.
Maintains CHIP, with a planned
match-rate increase for states in
2015.
HR 3962: Require drug
manufacturers to provide rebates
for dually eligible; Secretary to
negotiate drug prices directly with
manufacturers; halt agreements
between brand name and generic
manufacturers that obstruct
competition from generic
drugs. HR 3590: Penalty of $1 per
covered life for those health plans
that do not document compliance
with finance/admin standards;
eliminate the Medicare
Improvement Fund; develop
database capture/share data across
federal/state programs, increase
penalties for submitting false
claims, increase funding for antifraud activities.

Both are estimated by the
Congressional Budget Office to
reduce the federal budget deficit by
over $100B over ten years.

Overall Cost

HR 3692: Congressional Budget
Office estimates that the net cost
of the proposal to be $894B over
ten years. Net savings from
Medicare and Medicaid are
estimated at $426B over ten years.
The largest source of revenue
($461B over ten years) would
come from a 5.4% tax on families
with incomes over $1M and
individuals with incomes over
$500k.
HR 3590: Congressional Budget
Office estimates that the cost of
coverage components of the
proposal to be $871B over ten
years. Net savings from Medicare
and Medicaid are estimated at
$438B over ten years. Largest
source of revenue from excise tax
on high-cost insurance, amounting
to about $149B over ten years.

There are several similarities between HR 3962 and HR 3590 but some of the key
differences are: (1) HR 3590 was proposed to be phased in starting in 2014 instead of
2013; (2) HR 3590 established compliance thresholds for employers that have less than
50 employees; (3) HR 3962 proposed financing health care reform by applying a 5.4%
gross income tax on individuals making more than $500,000 or families making more
than $1,000,000 annually. HR 3590 proposed financing health care reform by applying
an excise tax on “Cadillac” health care plans, pharmaceutical companies, medical device
makers, and the insurance sector; (4) HR 3590 proposed paying hospitals based on
performance and quality measures; (5) the cost of HR 3692 would be fully funded by the
federal government the first year and then shift to 91% federal / 9% state matching
model. HR 3590 would be covered 100% by the federal government for the first three
years; and (6) HR 3590 proposed a net savings for Medicare and Medicaid of $438
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billion dollars over ten years. HR 3962 proposed a net savings for Medicare and
Medicaid of $426 billion dollars over ten years (Figure 11).

In February of 2010, President Obama proposed his own bill bridging both the
House and Senate’s bill. This increased the pressure on the U.S. House of
Representatives to pass health care reform legislation, which they did by amending the
Patient Protection and Affordable Care Act with Health Care and Education
Reconciliation Act of 2010 (Healthcare Reform, 2011). President Obama signed the final
version of the Patient Protection and Affordable Care Act (PPACA) on March 23, 2010
(GovTrack, 2013).

Proponents and Opponents of the Legislation

The simplest way to describe the political division created by PPACA, is
Democrats are for healthcare reform and the Republicans are against it. Reviewing the
U.S. Senate and U.S. House of Representatives vote record for both the Patient Protection
and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010,
where no Republican Representatives or Senators voted in favor of either bill, it is clear
that the Republican Party opposes health care reform and the Democratic Party supports
it (GovTrack, 2013). Health care reform strikes at the core ideologies of both parties. For
the Republicans, health care reform represents the expansion of government, increased
taxation, and negative financial impact to businesses. For the Democrats, health care
reform provides the expansion of health insurance to millions of uninsured citizens
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creating greater access to medical treatment, increases the cost sharing for medical
treatment with the industries that are directly benefiting from the high cost of health care
in the United States, and introduces the model of fee for value versus fee for services by
associating reimbursements with the quality of care received. Opposition to PPACA
resulted in the U.S. House of Representatives approving The Repealing the Job-Killing
Health Care Law Act in January of 2011 after the Republican Party regained the
majority. The Repealing the Job-Killing Health Care Law Act was subsequently rejected
by the U.S. Senate in a 51-47 party-line vote (Healthcare Reform, 2011).

In addition to the attempted repeal of PPACA, opponents also argued that
Congress did not have the authority to enact the individual mandate that all citizens are
required to participate in health coverage or be subject to a fine. Opponents point to the
lack of provision(s) within the U.S. Constitution guaranteeing a right to health care
services provided by the government to those who cannot afford it. Proponents argue that
based on the Commerce Clause and the Necessary and Proper Clause, Congress does
have the authority to enact such laws (Burgess, 2013). The Commerce Clause gives
Congress the authority “to regulate commerce with foreign nations, and among the
several states, and with the Indian tribes” (Commerce Clause, 2013) and the Necessary
and Proper Clause states that Congress has the power “to make all laws which shall be
necessary and proper for carrying into Execution the foregoing Powers, and all other
Powers vested by this Constitution in the Government of the United States, or any
Department or Officer thereof.” (Necessary and Proper Clause, 2013) Six challenges to
PPACA were submitted to the U.S. District Courts, of which the Sixth Circuit Court of
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Appeals in Cincinnati, OH upheld the entirety of PPACA but the Eleventh Circuit Court
of Appeals in Atlanta, GA found the individual mandate to be unconstitutional (Burgess,
2013). In response to the Eleventh Circuit Court’s ruling, the Supreme Court was
petitioned by the Justice Department to decide the constitutionality of the individual
mandate within PPACA. The Supreme Court heard arguments, for and against, the
constitutionality of the individual mandate and on June 28, 2012 Justice John Roberts
summarized the ruling in his concluding opinion as follows:

“The Affordable Care Act is constitutional in part and unconstitutional in
part. The individual mandate cannot be upheld as an exercise of
Congress’s power under the Commerce Clause. The Clause authorizes
Congress to regulate interstate commerce, not to order individuals to
engage in it. In this case, however, it is reasonable to construe what
Congress has done as increasing taxes on those who have a certain amount
of income, but choose to go without health insurance. Such legislation is
within Congress’s power to tax.” (Roberts, 2012)

Due to the lack severability in PPACA, if any component of the act is found
unconstitutional the act in its entirety is at risk. The Supreme Court ruling addressed the
constitutionality of the individual mandate based on the Commerce Clause but the ruling
did not eliminate the potential for further litigation. As part of this ruling, the Supreme
Court also ruled that state participation in Medicaid expansion is optional and that states
choosing to not participate cannot be penalized (Roberts, 2012).

At the state level, many Governors refused to accept the Medicaid expansion
funds offered under PPACA. The Medicaid expansion program was effective January
2014 providing increased medical access to the poorest Americans by broadening
Medicaid eligibility to individuals less than sixty-five years of age with income below
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133% of the federal poverty level. The financial impact to individual states will begin in
year four of the program when the 100% federal funding shifts to a shared funding model
ultimately resulting in PPACA receiving 90% federal and 10% state funding in the year
2020. The expansion of Medicaid creates greater access for the uninsured but increases
the federal and state financial burden to provide funding for treatment reimbursements.
South Carolina would add an estimated 500,000 individuals to Medicaid by opting into
the expansion, but the cost of covering 10% of the program is estimated to reach $1.7
billion dollars by the year 2020 (The State Paper, 2013). Proponents of expanding
Medicaid in South Carolina estimate that the total economic output of opting in would be
$3.3 million dollars and support nearly 44,000 jobs (SCHA, 2012). The expansion of
Medicaid is a critical debate among health care providers who are concerned about the
increasing demand to provide quality health care for uninsured/underinsured individuals
while maintaining financial viability. Hospitals across the state are addressing the
pending reduction in reimbursements as the industry shifts from fee for service to fee for
value by initiating cost saving programs.

Finance

It is estimated that without the implementation of health care reform legislation,
the combined expense of Medicare, Medicaid and Social Security would exceed the
projected tax revenue of 18.2% in approximately 2050 (Hartung, 2012). As noted in
Figure 4, the payer mix from the period of 1999-2011 has seen a 9% decrease in
employer sponsored insurance and a 10.10% increase in government insurance and the
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uninsured, combined. This trend demonstrates that employer sponsored health insurance
is declining and individuals are either receiving health care through government
insurance programs or are foregoing health insurance. The impact of an increasing
uninsured population translates to individuals being limited in their health care spending.
This limitation results in a percentage of the population that only obtains episodic care
when it is absolutely necessary, avoiding the expense of preventive care.

Figure 4: Insurance Trends, 1999-2011

Notes: Data is for the entire US population. Percentages do not add up to 100% because some people
have more than one type of coverage. In 2010, the Census Bureau updated its coverage data for current
and prior years to reflect changes in the methods used to impute health insurance for non-respondents.
Government insurance includes military coverage. (U.S. Census Bureau, 2011)

PPACA addresses the trends described above by establishing the requirement that
U.S. citizens and legal residents must have health insurance. This is accomplished by
requiring states to establish state-based health insurance exchanges that provide cost
effective purchasing options for individuals and small businesses to reduce the financial
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burden associated with paying health insurance premiums. For those individuals and
employers that choose not to participate in the insurance exchanges, individual and
employer mandates to maintain health insurance will be instituted as part of PPACA. The
individual mandate will require U.S. citizens and legal residents to have qualifying health
coverage or pay a maximum annual tax penalty of $2,085 or 2.5% of household income.
The tax penalty will be phased in over a three-year period starting in 2014. After 2016,
the penalty will increase based on the cost-of-living adjustment (Kaiser Family
Foundation, 2011). Employers with fifty or more full-time employees that do not offer
health insurance will be assessed a fee of $2,000 per employee and employers with more
than two hundred employees will be required to automatically enroll employees into
company provided health plans (Kaiser Family Foundation, 2011). Small businesses with
less than twenty-five employees and average annual wages less than $50,000 will receive
a tax credit for purchasing employee health insurance. Individuals with incomes up to
133% of federal poverty level will be eligible for Medicaid coverage under PPACA
Medicaid expansion provision. This will insure that individuals that are not able to
purchase insurance through the state health insurance exchanges will be eligible to
receive essential health benefits. As stated previously, Medicaid expansion will be
federally funded for the first three years, transitioning to a 90% federal / 10% state
supported program by the year 2020.

PPACA improves affordability of medication for seniors by reducing the gap
known as the “donut hole” in Medicare Part D. As a result of the changes to Medicare
part D people in the “donut hole” received a 50% discount on covered brand name drugs
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and 14% discount on generic drugs in 2012. The financial gain of this improvement
translates to a $5.7 million dollar savings on prescription drugs over the past two years
(Healthcare.Gov, 2013). In addition to improving the affordability of medications,
PPACA requires insurance plans to eliminate cost sharing (deductibles and co-pays) for a
variety of preventive health services. In 2011 and 2012, 71 million Americans that were
enrolled in private health insurance obtained preventive health services without cost
sharing (Healthcare.Gov, 2013).

Delivery

To accommodate the increase in patient volumes due to greater access to medical
care, PPACA addresses the workforce impact by providing the following provisions: (1)
through the establishment of a multi-stakeholder Workforce Advisory Committee,
develop a national workforce strategy; (2) redistribute unused General Medical Education
(GME) slots to states with the lowest resident physician-to-population ratios, with
primary care and general surgery being prioritized; (3) increase the number of Teaching
Health Centers, defined as community-based, ambulatory patient care centers that are
reimbursed under the same guidelines as primary care residency programs; (4) expand
health professional workforce supply and support training via scholarships and loans
providing specific focus to preventive medicine, public health, and interdisciplinary
mental and behavioral health training; (5) prepare for the projected shortage of nurses by
increasing the availability of nursing education programs, providing loan repayment
assistance, and establishing a career ladder to nursing. Increase grant opportunities to
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train family nurse practitioners that are willing provide care in federally qualified health
centers and nurse-managed clinics; and (6) increase the support for the development of
primary care training models that focus on medical homes, coordinated management of
chronic disease, and programs that address both physical and mental health (Kaiser
Family Foundation, 2011).

The National Health Services Corps is a great example of how workforce
provisions of PPACA are making a difference. The National Health Service Corps is a
federal government program that is part of the Department of Health and Human
Services. Due to the investments from PPACA, nearly 10,000 Corps clinicians are
providing care to more than 10.4 million people located in rural, urban and frontier
communities (Healthcare.Gov, 2013). The expansion of the National Health Service
Corps is in direct response to increased federal funding to repay educational loans and
provide scholarships to clinicians that practice in areas of the country that do not have
enough medical professionals to serve the people who live there. Specifically, The
National Health Service Corps will receive $1.5 billion dollars over a five-year period,
starting in 2011, in support of continued expansion into medically underserved areas
(Kaiser Family Foundation, 2011).

Information Technology is a focal point of delivery under PPACA through the
establishment of ACO’s. Elliot S. Fisher first described the term ACO in 2007 as “the
United States Health Care System suffers from serious gaps in quality and widespread
waste stimulating a broad array of public - and private - sector initiatives to improve
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performance. These include not only public reporting, pay-for-performance (P4P), and
quality improvement programs but also major initiatives by the organizations responsible
for institutional accreditation and professional certification” (Fisher, 2007). Under the
guidance of The Centers for Medicare and Medicaid Services (CMS), health
organizations can utilize electronic medical record solutions that are meaningful in use to
exchange patient data and coordinate care. The coordination in care is meant to establish
specific cost saving benefits through the reduction of duplication in services and establish
a preventive health care model to replace the current reactionary model (Hartung, 2012).
The specifics of the CMS proposal for ACO’s is: (1) have a minimum of 5000 patients,
all participants must have a medical home; (2) meet a minimum standard with respect to
65 quality measures before being eligible to receive bonus payments; (3) produce
minimum savings targets based on the quantity of patients participating; (4) establish and
maintain a governing body that consists of 75% ACO participants with at least one
patient participating on the governing board; (5) cannot exclude at risk patients from
participating; and (6) must retain at least 25% of bonus payments as escrow for future
losses (Medicare Program, 2011).

Quality

The need for a national quality improvement strategy is identified as part of
PPACA and prioritizes the improvement of delivering health care services, patient health
outcomes, and population health (Kaiser Family Foundation, 2011). PPACA prioritizes
the improvement of overall health in an effort to reduce the expense of providing care. By
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addressing the quality of care and gradually transforming the health care industry to a
more preventive care model, patient outcomes will improve. The focus on quality is
apparent by the increased value placed on reimbursement based on core measures of
quality and the objectives of the stages of “Meaningful Use” identified as part of the
HITECH Act.

The establishment of preventive care under PPACA is supported by the
following: (1) eliminate preventive service cost-sharing under Medicare to promote
access to essential preventive health screenings; (2) states that provide Medicaid
coverage for preventive services can eliminate cost-sharing; (3) establish an annual
comprehensive health risk assessment for Medicare participants; (4) provide behavior
modification incentives for both Medicare and Medicaid enrollees; and (5) require
qualified health plans to eliminate cost sharing for preventive services such as
recommended immunizations, preventive care for infants and adolescents, and preventive
care for women (Kaiser Family Foundation, 2011). In addition to offering preventive care
measures, PPACA penalizes hospitals by reducing Medicare reimbursements for
preventable hospital readmissions and hospital-acquired conditions. Both preventive care
and the reduction of preventable hospital admissions require improved management of
chronic diseases. Without chronic disease management a very small percentage of
individuals within any health plan incur the majority of the expense. Through chronic
disease management, the need of emergent care or prolonged episodic care can be
reduced.
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Accountable Care Organizations

Centers for Medicare and Medicaid Services define ACOs as “groups of doctors,
hospitals, and other health care providers, who come together voluntarily to give
coordinated care to their Medicare patients. The goal of coordinated care is to ensure that
patients, especially the chronically ill, get the right care at the right time, while avoiding
unnecessary duplication of services and preventing medical errors.” (CMS, 2015). The
incentive for health care providers and organizations to participate is the potential of
increased reimbursement by sharing any savings associated with the reduction in patient
care expense.

ACOs take the pay-for-performance model beyond the health care provider and
introduce the idea of significantly reducing the overall expense of health care by
integrating into the workplace, home and communities (McLellan, 2012). “It envisions
the medical home as a central locus in a spectrum of health care services applying
evidence-based approaches in joint ventures among organizations that decrease the
fragmentation of the current system” (McLellan, 2012). Elements of an ACO are: (1)
Care teams composed of primary care physicians, physician assistants, nurse
practitioners, specialists, and others who coordinate patient care, (2) added focus on
evidence based medicine, quality outcomes and safety, (3) increased use of information
technology and (4) reduction of high-volume and high-profit margin services with a new
emphasis on value and outcomes (McLellan, 2012).
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While the origination of ACOs is linked to Medicare patients, it is not specifically
a Medicare only initiative. The following section will describe the tools utilized in ACOs
to evaluate overall health of participants and the coordination of care, how the ACO
model is related to this project, and how the utilization of the ACO model differentiates
this project from other wellness programs described previously.

Accountable Care Organization Tools

The premise of an ACO is that if the right patient care is delivered at the right
time, expense will decrease and outcome quality will improve. To accomplish this,
ACO’s utilize patient risk modeling tools to identify high-risk patients, both current and
potential, and provider coordination tools to assist in coordinating and tracking the care
received to manage chronic illnesses.

Risk modeling is accomplished by using a variety of commercially available
software tools. These tools utilize proprietary algorithms that assess health services
claims data to determine the risk associated with a given patient and identify health care
trends that may indicate specific disease maintenance. The claims data is collected using
a specific submission file type, Health Claim Transaction Set (837) that was established
as part of the HIPAA Act of 1996. The 837 transaction set includes the following items
for a single care encounter between patient and provider: (1) a description of the patient,
(2) the patient’s condition for which treatment was provided, (3) the services provided,
and (4) the cost of the treatment (1EDISCOURCE, 2015). The detailed specification for
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the content and the uses of an 837 file is, “The X12 Transaction contains the format and
establishes the data contents of the Health Care Claim Transaction Set (837) for use
within the context of an Electronic Data Interchange (EDI) environment. This transaction
set can be used to submit health care claim billing information, encounter information, or
both, from providers of health care services to payers, either directly or via intermediary
billers and claims clearinghouses. It can also be used to transmit health care claims and
billing payment information between payers with different payment responsibilities
where coordination of benefits is required or between payers and regulatory agencies to
monitor the rendering, billing, and/or payment of health care services within a specific
health care/insurance industry segment. For purposes of this standard, providers of health
care products or services may include entities such as physicians, hospitals and other
medical facilities or suppliers, dentists, and pharmacies, and entities providing medical
information to meet regulatory requirements. The payer refers to a third party entity that
pays claims or administers the insurance product or benefit or both. For example, a payer
may be an insurance company, health maintenance organization (HMO), preferred
provider organization (PPO), government agency (Medicare, Medicaid, Civilian Health
and Medical Program of the Uniformed Services (CHAMPUS), etc.) or an entity such as
a third party administrator (TPA) or third party organization (TPO) that may be
contracted by one of those groups. A regulatory agency is an entity responsible, by law or
rule, for administering and monitoring a statutory benefits program or a specific health
care/insurance industry segment.” (ASCX12, 2015) In addition to utilizing EDI 837 files,
adjudicated claims from individual payers also provide an indication of the types and cost
of care being received. Adjudicated claims are the finalized reconciliation of service and
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payments that are agreed upon by the provider and the payer. This information is specific
to items that occurred in the past so it is not appropriate for assessing current health
issues but provides a significant retrospective view by payer. By collecting this
information, it is possible to evaluate both the care and the cost associated with medical
treatment and assign a risk score for the individual patient, accordingly. Those
individuals scoring higher in a risk scale can then be evaluated to determine if the score is
related to specific episodic care, chronic disease management, or excessive use of health
care services.

Utilizing the risk modeling tools identifies individuals that may benefit from
additional care planning or care management. Physicians and care managers utilize
information system care coordination tools that require additional clinical information to
be available to provide a complete picture of the care each patient is receiving. The
challenge with these systems is the ability to collect all care information and provide a
complete clinical picture. To overcome this challenge, most care coordination tools are in
the form of an electronic dashboard that consolidates multiple sources of clinical
information into a single view. This allows physicians and care managers to evaluate care
received over a period of time as well as dive deeper into the details of any given episode.
Collecting all clinical information is achieved through a health information exchange
solution that receives clinical data via information system interfaces from electronic
health record systems. Conceptually, collecting clinical data and consolidating the
information into a single view is simplistic, but when considering the number of
physicians, clinics, and hospitals that may be utilized by an individual increases the
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complexity exponentially. The benefit of collecting the clinical information into an
electronic dashboard allows providers to evaluate prior clinical information collected by
other providers to potentially reduce duplication in services as well as create a source for
care coordination and patient compliance tracking. This can be demonstrated when a
primary care provider has the ability to review current medications, laboratory results,
and possibly condition monitoring by the patient.

Accountable Care Organizations and This Project

The focus of this project is to evaluate the return on investment for individuals
that are participating in a workplace wellness program to improve both the cost and
quality of life associated with diabetes disease management. The accountable care tools
described previously are utilized in this process by first assigning a risk score for
individuals of a specific population within an organization via a commercially available
ACO risk management tool. Once the individuals with high-risk scores are identified,
care coordination in the form of case managers can be established to assist with specific
disease management. The ACO model provides broader visibility to individual’s health
care utilization, which allows for a more holistic approach to care management.
Establishing the risk score using ACO tools prior to implementing care coordination also
provides the ability to track individual participant’s progress over a period of time versus
tracking disease specific diagnostic scores. Specifically, utilizing ongoing risk score
evaluations based on adjudicated claims or 837 files will provide insight into health care
visits, medication expenses, and laboratory results versus traditional diabetes disease
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management that consists of regular monitoring of glucose or A1C levels.

Difference from Other Diabetes Wellness Programs

Previous research utilizing PepsiCo’s HealthRoads workplace wellness program,
assesses the financial impact of workplace wellness programs, specifically diabetes, by
evaluating claims data and providing a self-administered health risk assessment (Liu, et
al., 2013). Based on the results of the evaluation and health risk assessment, individuals
were eligible for case management, disease management, lifestyle management, and a
nurse advice line. The program did not utilize commercially available ACO tools to
assess the claims data or evaluate overall success of the program. The research completed
by Liu et al. (2013) only evaluated the benefit side of a cost-benefit equation and was
unable to estimate the return on investment due to not having access to the related
program costs.

Additional workplace wellness programs discussed previously, identify the top
four categories of health quality improvements as, increased exercise level, health risk
reduction, smoking cessation, and decreased blood pressure (Kaspin, Gorman, and
Miller, 2013). Diabetes disease management is a relatively new focus area of workplace
wellness programs that requires a higher level of participant support systems to improve
the management of the disease. The coordinated care team, provided to participants as a
support system, is focused on improving the access to care as well as reducing the cost of
care to manage a healthy lifestyle which is a commonality between ACO’s and
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workplace wellness programs. Utilizing an ACO model within a specified workplace
with access to the program costs information and clinical data will provide better insight
into the return on investment associated with a workplace wellness program focused on
diabetes disease management.
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METHODOLOGY

Population

The population of this study to answer the research question, “Can using an ACO
commercially available software tool and a diabetes wellness workplace management
program be combined to identify 1 year ROI in a sample of patients within an average
size institution?” is a subset of individuals that receive health benefits from a self-insured
employer at a reduced insurance premium. To participate in the reduced insurance
premium plan, individuals that have at least one or any combination of the following
physiological indicators: a BMI greater than or equal to 50, a glucose of greater than or
equal 200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by
the CCMS commercial ACO software must comply with a workplace wellness program.
The workplace wellness program is provided by the employer in an effort to improve the
management of workforce health and assist employees that need focused care
management for diabetes. Focused care management is accomplished by assigning health
coaches to employees that qualify for the program.

Study Design

In an attempt to answer the proposed research question, de-identified data
obtained will be evaluated using the outcome evaluation model. The outcome evaluation
model, which is also known as an impact assessment, “focuses on the accomplishments
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and impact of the service program, or policy and its effectiveness in attaining the
intended results that were set prior to program or policy implementation” (Shi, 2008). It
allows for an evaluation of an enhanced or modified program compared to standard
program methods. The outcome evaluation model allows the program to be evaluated
based on the benefits of the intervention to determine if the program changes are an
improvement of the program. Specifically, outcome evaluations are interested in
answering the following questions: (1) What are the goals and objectives of the
program?, (2) How are they measured and assessed?, (3) What alternative programs are
available to this program?, (4) How are the essential components of the program related
to achieving goals and objectives?, (5) How successful is the program in accomplishing
intended results?, (6) How effective is the program?, (7) How costly is the program?, (8)
Which program components best accomplish goals?, (9) What gaps exist in meeting the
goals?, (10) What changes should be made to improve the efficiency of meeting program
goals?, (11) What are the positive and negative unanticipated outcomes of the program?,
and (12) What decisions can be made regarding the program continuation or expansion?
(Shi, 2008). Outcomes research performed at the patient level is generally focused on the
most prevalent, costly, medical conditions that have alternative clinical strategies. This
type of research involves linking the care received by a variety of patients with a
particular condition to positive and negative outcomes in order to determine what
interventions work best for patients (Guadagnoli and McNeil, 1994).

The purpose of the evaluation described in more detail later in this Methods
section, is to compare retrospective cost data of providing health care for diabetics in the
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study, prior to and after twelve months of participating in the program, in an effort to
calculate the return on investment utilizing a diabetic ACO model. In addition to
determining the return on investment, using the outcome evaluation model will also
provide insight into the strengths and weaknesses of the program as well whether to
continue the program as originally implemented.

It has also been noted that outcome research is concerned with the “movement to
managed care and the organization of previously independent health care providers into
integrated networks” (Shi, 2008) which can range from the older model of managed care
solutions into the most recently proposed ACO model. As mentioned previously, a key
goal of the ACO model is to change the health care reimbursement model from a fee for
service model to a pay for performance reimbursement model focused on the reduction of
overall individual health care expenses via proactive health and/or disease management.
To elicit the adoption of this new reimbursement model by providers requires this
assessment to determine if the additional expenses associated with providing care
management results in a positive return of investment.

The actual evaluation of the data will be performed as a repeated measures
longitudinal study (Shi, 2008), which will allow for a review of program participants
A1C values over a twelve-month period during the time frame of October 2013 to
September 2014. The data collected from the individual participant will be used to trend
the impact of care management on each individual participant’s A1C for those identified
with a BMI greater than or equal to 50, a glucose of greater than or equal 200 mg/dL, and
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an A1C equal to or greater than 7.0, during an annual work place wellness health
assessment. The longitudinal trend analysis will be based on the prior year health care
cost compared to the health care and program cost for the twelve-month program period
for each participant. The data will be an A1C score recorded, at least quarterly, for each
participant and trended for a twelve-month period. This information will be matched to
the specific care management interventions that were provided during the same period.
Based on both sets of data, an additional ACO risk score will be calculated at the end of
the evaluation period to determine if the program expenses incurred per participant
results in an improvement in the overall, prior to program participation, medical care
costs associated with the treatment of diabetes. The ACO risk score is calculated using a
commercially provided software tool with proprietary algorithms that assess health
services claims data to determine the risk associated with a given patient and identify
health care trends that may indicate specific disease maintenance. The claims data is
collected using a specific submission file type, Health Claim Transaction Set (837) that
includes the following items for a single care encounter between patient and provider: (1)
a description of the patient, (2) the patient’s condition for which treatment was provided,
(3) the services provided, and (4) the cost of the treatment (1EDISCOURCE, 2015). Due
to the proprietary nature of the algorithm used to calculate the risk score, it is difficult to
know all the factors, other than the 837 file, used to calculate the participant risk score. It
is assumed that participant age and corresponding diagnoses have an impact as well. This
design is best suited to answer the research question as it allows for the evaluation of the
pre and post program health care costs for diabetic patients that participate in a workplace
diabetes wellness program based on the utilization of ACO risk scoring software.
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Measures

Self Regional Healthcare, in partnership with McKesson, is an ACO
demonstration site. As a demonstration site, Self Regional Healthcare has decided to
validate the ACO model by enrolling all current team members in McKesson’s
Coordinated Care Management System (CCMS), which is a workflow tool that enables
payers to focus resources, better coordinate care through automation and effective
communication, integrate data at key points in the workflow, and base interventions on
evidence-based standards of care (McKesson, 2012). The CCMS solution collects
insurance claim data from insurance companies via technical interfaces, matching patient
claims and assessing the current patient diagnosis. It does this in an effort to provide
patient populations that are in need of specific health interventions to obtain improved
health through appropriate care management. Through the CCMS tool, individuals
receive a risk score based on their specific insurance claims information reported in an
industry standard 837 insurance claims file. Individuals that receive a high-risk score are
assigned a health coach that facilitates a specific care plan based on the specified
categorizations of obesity, hypertension, and diabetes. The health coach is responsible for
providing education to each participant that explains the program benefits. During the
initial meeting, each participant is interviewed by the health coach. The health coach
assesses current limitations of access to appropriate health care or lifestyle challenges for
each participant and offers solutions or guidance to obtain better health. The interventions
provided by the health coach range from providing access to a primary care provider and
medication assistance to gym membership and appropriate footwear to facilitate a more
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active lifestyle. The health coach maintains regular contact with each participant,
monthly if possible but quarterly at a minimum, to assess each individual participant’s
progress and compliance with improving diabetes management and overall health.

In addition to analyzing Self Regional Healthcare team member’s 837 insurance
claims file using McKesson’s CCMS tool, each team member covered under the
corporate health insurance plan is required to complete a health risk assessment that
includes the collection of key health indicators such as: weight, blood pressure, body
mass index (BMI), lipid panel, and A1C. Individuals that have a BMI greater than or
equal to 50, a glucose of greater than or equal 200 mg/dL, or an A1C equal to or greater
than 7.0 are also provided a health coach to assist in disease management specific to
diabetes. Having values greater than those required to participate in the program does not
always correlate with a high-risk score. For this reason participants of the study may not
have both a high-risk score and correlating physiological values.

To be included as a participant in the research, the Self Regional team member
needs to be enrolled in the program for at least twelve months and have any of the four
following indicators; a BMI greater than or equal to 50, a glucose of greater than or equal
200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by the
CCMS commercial ACO software. The program was initiated in 2013 and enrolled team
members in the first year it was established as well as during the second year in 2014.
Table 6 lists the specific research measures that will be collected for each participant
during the research period.
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Table 6: Research Measures for Each Participant
Measures

Scales

Participant characteristics

Age, sex, and race

Length of time in the program for each
participant

Reported in months

Initial results of health risk assessment for each
participant

Reported as a numeric value

Initial risk score as determined by commercial
ACO software
Risk score as determined by commercial ACO
software after 12 month participation in the
workplace wellness program
Weight loss while participating in the program
Physical activity while participating in the
program
Annual health care cost for each participant
while participating in the program
Total cost of ownership for the ACO software

Full time equivalents associated with the care
management staff of the program
Health insurance premium reduction for each
participant (incentive)

Program expense for each participant
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Reported as a numeric value
Reported as a numeric value
Reported in pounds
Number a daily steps or physical
activity as reported by the
Walkingspree program
Dollar amount for health care provided
as reported in the participant’s 837 file
Dollar amount of McKesson CCMS
product. Initial capital cost plus the
maintenance cost for the program
period
Compensation, including benefits, for
each full time equivalent health coach
and program manager
Dollar amount of reduced monthly
health insurance premium as a result
for participating in the program
Dollar amount of the combined costs
for the following items if provided to
each participant: gym membership,
exercise shoes, reduced meal plan, and
reduced prescription co-pays

Data Collection

The data for this research is based on information collected from participant
records and health claims information, pre- and post-research time frame, as well clinical
information collected by the care managers during the research period. The data collected
is: health specific information (A1C and weight), intervention data (physical activity),
and health care costs (emergent, inpatient, and ambulatory care) as reported for payment
via 837 insurance files. In addition to the participant specific health, intervention, and
claims data, the associated risk score as determined by the CCMS product, is collected
for each participant at the beginning and the end of the twelve month research period. As
submitted and approved by the IRB committees at Self Regional Healthcare and the
Medical University of South Carolina, the data is de-identified by the program
administrator prior to being analyzed.

During the study period, the health coach meets with each participant on a regular
basis, but no more than monthly, to collect program specific health data and assess if any
additional program interventions are needed. The care managers use a basic spreadsheet
tool to collect data during each of the interviews with the program participants. The data
collected is abstracted manually as needed to perform data analysis.

Data Analysis

Due to the lack of a control group associated with the specific research, data will

66

be evaluated using a before-and-after time-series comparison. Specifically, “pre-program
and post-program outcome measurements are compared to see if the differences are
significant.” (Shi, 2008). The main focus of the data analysis for this research will be
determining if the health care cost for each participant during the twelve months, October
2013 to September 2014, leading up to initiating the program is reduced as a result of the
program interventions and if the post-program health care expense in addition to the
program expense provides a positive return on investment. In addition to evaluating the
return on investment, descriptive data, specifically minimum, median or mean, and
maximum of each measure, will be determined to provide a detailed understand of the
study data. To determine if there is a significant difference in individual participant
medical cost pre- and post- intervention, a two-tailed T-test will be completed (Shi,
2008).

The tool utilized to evaluate the return on investment of the diabetes wellness
management program is a cost benefit analysis (CBA) which allows for the benefits and
the costs of the program to be quantified and translated into a common monetary unit.
Using the cost benefit analysis as the evaluation tool assists in the decision making
process for the planning, implementation, continuation, and expansion of health service
programs (Shi, 2008).

The cost benefit analysis will be assessed by determining: the total health care
cost for the program participants prior to program initiation (Y 0 ); the health care cost for
the program participants during the program period (Y 1 ); and the total cost of the
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program including software expense (P s ), program personnel (P p ), and program
incentives (P i ). Using these factors, the following formula will be used to calculate the
program cost benefit analysis which will be used to answer the research question
proposed previously:

CBA = Y 0 – (Y 1 +P s +P p +P i )

Using this formula, it will be possible to determine if the cost of implementing the
diabetes workplace wellness program combined with the reduced health care costs of all
the participants is less expensive than the health care cost of the participants prior to
initiating the program. If the CBA is a positive number than the program reduced the
expense of managing the participant population.

While the CBA formula evaluates the cost of implementing the diabetes
workplace wellness program, it does not account for calculating the actual return on
investment of the program for the study period. To determine the ROI of the diabetes
wellness program the ROI formula below was used.

Return on Investment = (Investment Gain – Investment Cost)
Investment Cost
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RESULTS

Participant Descriptive Data

The participants included in this project are part of a diabetes workplace wellness
program at Self Regional Healthcare, Self Cares. Self Cares is an incentive based
workplace wellness program to maintain healthy habits in return for reduced health
insurance premium. As part of the program, any individual identified having at least one
of the following physiological measures as reported during Self Regional Healthcare’s
annual health assessment: a BMI greater than or equal to 50, a glucose of greater than or
equal 200 mg/dL, an A1C equal to or greater than 7.0, and a risk score as calculated by
the CCMS commercial ACO software, were required to participate in a focused diabetes
workplace wellness program that included health coaches to assist with eliminating
barriers to improved health behaviors.

From the original group of Self Cares participants, fifty individuals qualified for
the focused diabetes workplace wellness program. Of the fifty individuals identified,
twenty-eight participated in the program for at least the first twelve months from October
2013 to September 2014 and had pre-program data and post-program data. The data
points required for the analysis where: weight, A1C, health care and medication expense,
CCMS risk score, diabetes workplace wellness program expense. The demographics for
the twenty-eight participants were: 54% (n=15) Caucasian, non-Hispanic, 46% (n=13)
African American, 29% (n=8) male, and 71% (n=20) female. The age of the twenty-eight
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participants ranged from the youngest being twenty-five years old and the oldest being
sixty-four years old at the beginning of the program. The median age of the participant
group was forty-nine years old. The largest grouping of the participants was from forty to
fifty-nine years old as shown in Table 7.

Table 7: Summary of Program Participant Data
Age Group (years of age)
25 – 29
30 – 34
35 – 39
40 – 44
45 – 49
50 – 54
55 - 59
60 - 64
N=
Minimum
Median
Maximum

Program Participants
by Age Group
3
3
3
4
4
5
6
2
28
25 years of age
49 years of age
64 years of age

Percentage by Age Group
10.71%
7.14%
7.14%
14.29%
14.29%
17.86%
21.43%
7.14%
100%

The annual health assessment that all Self Regional Healthcare employees are
required to complete collects: weight, blood pressure, BMI, glucose, cholesterol,
LDL/HDL, triglycerides, and A1C. Table 8 provides a summary of the initial health
assessment data for the twenty-eight participants in the diabetes workplace wellness
program. The minimum, median, and maximum values are calculated based on the
individual value by category not as a collective set of values for an individual participant.
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Table 8: Summary of Initial Health Assessment Data
Weight Syst/
(lbs.)
Diast
174
115/55
Minimum
253
143/76
Median
388
176/100
Maximum

BMI
25
41
58

Gluc
mg/dL
80
191
328

Chol

LDL/HDL

Trig

A1C

99
166
419

29/17
96/39
145/77

53
107
3456

5.9
8.15
14.5

When reviewing the raw data, it is interesting that the participant with the lowest
weight (174 lbs.) also has the lowest BMI (25) but has an A1C of 8.0 which is very close
to the median (8.1) for the group. This participant’s glucose is reported as 142 mg/dL
which is below the recommend diabetic threshold of 200mg/dL. This participant’s data
validates the need to evaluate multiple physiological indicators versus a single indicator
when assessing an individual’s ability to process glucose. The reported data for this
individual is also an example of how A1C and fasting glucose screenings can contra
indicate each other as previously discussed. A fasting glucose of 200mg/dL or greater and
an A1C of 7.0 or greater results in a diagnosis of diabetes. This participant has a glucose
of 142mg/dL, well below the established diabetic threshold, and an A1C of 8.0 which is
above the diabetic threshold of 7.0.

Program Specific Data

The program specific data collected for the diabetes workplace wellness program
was pre- and post- program values for weight comparison, recorded step counts as a
measure of physical activity, A1C scores, risk score as calculated by the CCMS software,
health care costs as reported by the participants individual 837 file submissions, and
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pharmaceutical costs as recorded by Self Regional Healthcare’s health insurance
provider. The purpose of collecting the pre and post program data is to evaluate the
impact of the diabetes workplace wellness program on the participant’s specific collected
physiological values.

Overall, as a group, the twenty-eight participants of the study had a mean weight
of 269 pounds pre-program and a mean weight of 271 pounds after the first twelve
months. The difference between pre- and post- program mean weight was an increase of
a 1.6 pounds, see Table 9. Although there was a mean increase from the beginning of the
program several participants succeeded in losing weight over the twelve month program.
Eleven participants lost weight during the program. The weight loss by participant ranged
from 1.0 pound to the maximum loss of 19 pounds. In contrast, seventeen of the
participants gained weight during the program. Those participants that gained weight saw
an increase ranging from 1.0 pound to 25 pounds. One participant was recorded as
maintaining weight with a weight of 202 pounds during the initial health assessment and
after twelve program months.

Table 9: Participant Weight Comparison
Participant
Identifier
Minimum
Mean
Maximum

Pre-Program
Weight (lbs.)
174
269
388

Post-Program
Weight (lbs.)
175
271
413
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Weight
Difference (lbs.)
-19
1.6
25

As part of the diabetes workplace wellness program, participants were provided
pedometers that facilitated physical activity reporting on a quarterly basis over the twelve
months of the program. Table 10 provides a summary of the results of the quarterly
tracking of participant step counts as recorded on personal pedometers. The mean step
count for each quarter was reported as 624,993 steps in the first quarter decreasing to
491,371 steps in the fourth quarter of the program. Similarly to the decrease in total steps
per quarter, the mean for the daily step average of the twenty-eight participants was 6,844
in the first quarter declining to 4,791 in the last three months of the twelve month
program. Only one participant did not record any steps for the twelve months of the
program. Three quarters of the program participants (75%) recorded steps for the
duration of the program. A point of interest from the data was three of the four quarters
of maximum steps was completed by the same program participant with the first quarter
step count for this participant being 15,290 steps less than the maximum reported.

Table 10: Participant Step Count Summary
Participant
Identifier
Minimum
Mean
Maximum

Total
Steps
Q1

Daily
Aver
Q1

Total
Steps
Q2

Daily
Aver
Q2

Total
Steps
Q3

Daily
Aver
Q3

Total
Steps
Q4

Daily
Aver
Q4

0
624993
1222178

0
6844
13285

0
532883
1369752

0
5941
15219

0
516278
1369752

0
5298
15219

0
491371
1178633

0
4791
12952

To evaluate the improvement of diabetes disease management as part of the
diabetes workplace wellness program, A1C scores were recorded during the initial health
assessment and used to identify program candidates that had a value equal to or greater
than 7.0. To evaluate the impact of the program on the blood glucose management for
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each participant, A1C values were also collected after twelve months of the program. It is
important to note that not all participants had an A1C equal to or greater than 7.0 but the
lowest A1C reported at the initiation of the program was 5.9 which close to the A1C
range (6.0 to 6.5) that is used to qualify an individual as pre-diabetic and at risk for
developing Type 2 diabetes.

The pre-program A1C mean for the twenty-eight participants was 8.5 with a 0.7
mean improvement over the twelve month program (Table 11). The greatest reduction by
a single participant in A1C over the program period was 5.6, from 14.5 to 8.9. With one
participant recording an increase in A1C from 6.3 to 8.5. Overall 64% of participants
experienced a reduction in A1C during the program period with two participants seeing
no change. Both of these participants recorded a pre- and post-program A1C of 6.0. Six
of the participants that recorded an initial A1C equal to or greater than 10.0 had a
reduction in A1C greater than or equal to 1.0, see Table 16. It is also important to note
that the pre-program maximum A1C value was 14.5 and the maximum post-program
value was 11.1.
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Table 11: Participant A1C Comparison
Participant
Identifier
CHP15746290901
CHP25178081501
CHP21482500701
CHP25008433601
CHP25053503301
CHP24723330601
CHP25021709601
CHP25041451701
CHP41664936301
CHP24745113901
CHP24841728501
CHP24813901301
CHP25080979301
CHP43169645401
CHP24785613901
CHP26023799601
CHP24943148401
CHP24841256101
CHP24704060101
CHP24911060701
CHP06460042601
CHP25092857801
CHP30904538401
CHP13070296401
CHP24781670701
CHP25117954601
CHP24711478601
CHP24955270901
Minimum
Mean
Maximum

Pre-Program
A1C
6.6
10.2
8.5
6
9.3
6.4
11.1
9
11.1
6
7.9
8.4
8.2
9.7
6.3
6.8
12.1
11.7
6.3
6.2
8.1
11.9
7
8
5.9
14.5
10
6.1
5.9
8.5
14.5

Post-Program
A1C
6.3
8.6
7.1
6
9.5
6.8
10.1
8.7
10.2
6
8.6
8.5
7.2
9
8.5
6.6
8.7
10.6
5.7
6.3
7.5
11.1
6.3
7.6
6
8.9
6.3
6.4
5.7
7.8
11.1

A1C Difference
-0.3
-1.6
-1.4
0
0.2
0.4
-1
-0.3
-0.9
0
0.7
0.1
-1
-0.7
2.2
-0.2
-3.4
-1.1
-0.6
0.1
-0.6
-0.8
-0.7
-0.4
0.1
-5.6
-3.7
0.3
-5.6
-0.7
2.2

The risk score data reported as part of the program was determined by using the
commercially available risk ACO software, CCMS, provided by McKesson. The risk
score software uses the individual participant’s 837 insurance file and pharmaceutical
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claims data provided by the organizational health care insurance provider to calculate a
risk score that is used to rank the individual financial risk associated with an individual’s
health. While the risk score was not used as an identifier for program participants, it was
a key data point that needed to be analyzed to determine if the risk score is similar to
changes in the other program indicators, such as change in weight and A1C values for
each participant.

The pre-program risk scores for the twenty-eight participants ranged from 0.13 to
10.91 with a mean of 2.09 (Table 12). The higher the score, the greater the financial risk
of the individual participant. The post-program risks for the same group were from 0.65
to 12.25 with a mean of 2.35. As represented by the pre- and post-program mean values,
risks score for the twenty-eight participants increased over the twelve month program
period. In fact, only 29% of the program participants were successful in reducing their
individual risk score. The greatest decrease and increase in the risk score for the twentyeight program participants was -3.87 and 3.92, respectively.

Table 12: Participant Risk Score Summary
Participant
Identifier
Minimum
Mean
Maximum

Pre-Program
Risk Score
0.13
2.09
10.91

Post-Program
Risk Score
0.65
2.35
12.25

Risk Score
Difference
-3.87
0.26
3.92

Participant health care cost, including emergent, inpatient, and ambulatory care, is
analyzed by calculating the pre-program and post-program difference for all twenty-eight
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program participants. Total health care cost pre-program is $152,677. Total health care
cost after the twelve months of the program is $107,915 which resulted in a savings of
$44,763. It is important to note that the health care cost does not include the
pharmaceutical cost during the program. Since the health care cost and pharmaceutical
data was available separately, it was not combined to allow for an independent evaluation
of the associated cost. The mean health care cost pre-program was $5,453 compared to a
post-program mean of $3,854 which yields a mean pre- to post-program difference of
$1,599 (Table 13). The greatest cost savings recorded was $49,739 and the greatest
increase in health cost was $17,423. Without a detailed medical record chart abstraction,
it would be difficult to determine the exact cause of the cost savings or increase. Based
on the research question and the approved use of de-identified data by the IRB
committee, medical record chart abstraction is outside the scope of this project. Sixteen
of the twenty-eight participants (57%) did record a cost savings over the twelve months
of the program.

Table 13: Participant Health Care Cost Summary
Participant
Identifier
Minimum
Mean
Maximum

Pre-Program
Health Care
Cost
$41
$5,453
$64,300

Post-Program
Health Care
Cost
$228
$3,854
$28,477

Health Care
Cost Difference
-$49,739
-$1,599
$17,423

Similar to the health care cost analysis, pharmaceutical cost was calculated by
determining the difference between the pre-program pharmaceutical cost and post-
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program pharmaceutical cost. The data used for this analysis was provided by Self
Regional Healthcare’s insurance provider as a de-identified annual pharmaceutical cost
summary by program participant from October of 2012 to September of 2013 (preprogram) and October 2013 to September of 2014 (post-program), Table 14. Total
pharmaceutical cost pre-program is $114,753. Total pharmaceutical cost after the twelve
months of the program is $152,636 which is an increase year over year of $37,883. The
mean pharmaceutical cost for pre-program and post-program is $4,098 and $5,451,
respectively. The mean difference between pre- and post-program is an increase $1,353
which supports the recorded increase for all twenty-eight participants. Evaluating the
difference in pharmaceutical cost for the twenty-eight participants, 71% recorded an
increase. Of those that increased, thirteen of the twenty-eight participants had an increase
of $1,000 or greater in pharmaceutical cost with the greatest increase being $10,369.

Table 14: Participant Pharmaceutical Cost Summary
Participant
Identifier
Minimum
Mean
Maximum

Pre-Program
Pharmaceutical
Cost
$22
$4,098
$36,381
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Post-Program
Pharmaceutical
Cost
$247
$5,451
$31,543

Pharmaceutical
Cost Difference
-$4,838
$1,353
$10,369

Statistical Analysis

To determine if there is a significant difference in individual A1C, risk score, and
participant’s weight as a result of the program, a two-tailed T-test was completed by
comparing the pre- and post-program data. The results of the two-tailed T-test are
reported in Table 15. Evaluation of the reported results for the A1C data suggests a
statistical difference based on the P-Value being less than 0.05 and the T-Calculated Two
Tail Value of 2.58 being greater than the T-Critical Two Tail Value (2.05). The
difference for the risk score and weight was not determined to be statistically significant.
The mean difference for A1C, risk score, and weight is -0.7, 0.26, and 1.6 respectively
with the A1C data being the only data set to demonstrate a reduction in the A1C values
for the twenty-eight program participants.

Table 15: Two-Tailed T-Test Results of Program Specific Data
Data
Set

T-Critical
Two Tail
Value

P - Value

Lower
Confidence
Level

Upper
Confidence
Level

2.051830516
2.051830516

TCalculated
Two Tail
Value
2.583585604
1.09132171

A1C
Risk
Score
Weight

0.007756048
0.284774636

-1.294372296
-0.228206046

-0.148484847
0.746777474

2.051830516

0.817661404

0.420707917

-2.42580372

5.640089434

To evaluate the health care and pharmaceutical cost difference between pre- and
post-program participant data, the Wilcoxson Signed Rank Test was used. The
Wilcoxson Signed Rank Test is used to analyze the cost difference since it is a non-
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parametric version of the T-Test. The Wilcoxson Signed Rank Test compares a critical
value based on sample size and a calculated test value. If the calculated test value is less
than the critical value, sufficient evidence exists to suggest there is statistical difference
between the pre- and post-program cost data. The Wilcoxson Signed Rank Test critical
value for a sample size of twenty-eight is 116. The calculated test value for health care
cost and pharmaceutical cost is 171 and 78, respectively. This suggest that there is
statistical difference in the pharmaceutical cost data (78<116) but not the health care cost
data (171>116).

In addition to determining statistical differences in the A1C, risk score, weight,
health care cost, and pharmaceutical cost for the diabetes workplace wellness program,
correlation between the A1C and health care costs was evaluated. Using the Spearman
Rank Correlation Test to evaluate the correlation between the A1C values and health care
cost without assuming a linear relationship. Spearman’s Rank Correlation Test compares
a calculated value based on a 1 to -1 scale, where 1 and -1 implies a correlation of the
data and 0 implies no correlation. The calculated Spearman Correlation value for the preand post-program difference for A1C and health care cost is 0.073618 which is closer to
0 than 1 indicating little to no correlation between: (1) the difference between the A1C
values pre-program and post-program and (2) the difference in health care cost preprogram and post-program.
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Program Cost Data

The cost benefit analysis (Table 16) assesses: the total health care cost for the
program participants prior to program initiation (Y 0 ); the health care cost for the program
participants during the program period (Y 1 ); and the total cost of the program including
software expense (P s ), program personnel (P p ), and program incentives (P i ). Using these
factors, the following formula was used to calculate the program cost benefit analysis.

CBA = Y 0 – (Y 1 + P s + P p + P i )

P i is the program incentive for the twenty-eight participants. It includes: the
annual cost of gym memberships for those participants that enrolled as part of the
program, the total cost of sneaker vouchers provided to those participants that lacked
appropriate exercise footwear, and the $200 per month per participant reduced health
insurance premium. P i for the twenty-eight program participants equals $94,920.00 for
the twelve months of the program. P p is the labor expense for the employees that
administered the program which included the health coach and a .25 portion of a team
leader. The total program expense for P p was $117,944.00. P s is the cost to implement
the CCMS ACO software that was used to calculate each participants risk score. The total
cost of P s was $573,640.64. Y 1 is the total health care and pharmaceutical cost recorded
for each program participant of the twelve month program, equaling $260,550.90. Y 0 is
the same calculation as Y 1 accept it is using the pre-program health care and
pharmaceutical data. Y 0 equals $267,429.99. The calculated Cost Benefit of the diabetes
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workplace wellness program is a - $779,625.55. The resulting negative CBA value
indicates the diabetes workplace wellness program cost more in the first twelve months
than the savings associated with health care and pharmaceutical cost. It is important to
note that the cost difference of health care and pharmaceutical cost pre- and post-program
was a savings of $6,879.09.

Table 16: Program Cost Benefit Analysis
Y0
Gym
Membership
Sneakers
Reduced Insur.
Premium
1.25 FTE’s
Risk Software
Health Care
Expense
Pharmaceutical
Expense
CBA Total

Y1

Ps

Pp

Pi
$27,520
$200
$67,200

$117,944
$573,640.64
$152,677.47 $107,914.60
$114,752.52 $152,635.30
($779,625.55)

In addition to calculating the CBA of the diabetes workplace wellness program, a
return on investment calculation was needed to answer the research question, “Can using
an ACO commercially available software tool and a diabetes wellness workplace
management program be combined to identify 1 year ROI in a sample of patients within
an average size institution?” To determine the ROI of the diabetes wellness program the
ROI formula below was used.

Return on Investment = (Investment Gain – Investment Cost)
Investment Cost
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The investment gain for the program was the health care and pharmaceutical cost
savings of $6,879.09, previously discussed. The investment cost is the total cost of P s , P p ,
and P i (Table 21) which equals $786,504.64. Using the calculated investment gain and
investment cost, the ROI for the diabetes workplace wellness program is –99% as shown
below.
ROI = ($6,879.09 - $786,504.64)
$786,504.64
ROI = - 0.99

Although the program cost data does not indicate a significant cost savings or
return on investment for the diabetes workplace wellness program, it is important to
evaluate all data results of the program before assuming a lack of positive outcome.

In addition to calculating the ROI based on the savings and expenses associated
with the twelve month program, a sensitivity analysis was completed on the data
collected in an effort to understand the impact to ROI. The first sensitivity analysis was
focused on extrapolating the ROI over a five year period using the data collected as the
basis of the calculation. Table 16 provides the results of the analysis which is based on:
an annual growth in participants; expensing the commercial software (P s ) equally over a
five year period instead of in the first year as above and assuming the software cost is
static regardless of the number of program participants; increasing the program incentive
expense (P i ) according to the participant number; and increasing the labor cost (P p ) to
provide appropriate staffing as the program participants increase. The program savings is
determined by assuming the expense for each participant will be reduced by $248.68
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annually. This was calculated by using the total health care and pharmaceutical cost
savings and dividing it by the number of program participants, twenty-eight, yielding a
cost savings per participant.

Table 17: ROI Sensitivity Analysis

Number of Program
Participants
Ps
Pi
Pp
Program Savings

Year 1

Year 2

Year 3

Year 4

Year 5

100
$114,728
$339,000
$117,944
$24,568

250
$114,728
$847,500
$117,944
$61,420

500
$114,728
$1,695,000
$235,888
$122,841

750
$114,728
$2,542,500
$235,888
$184,261

1000
$114,728
$3,542,112
$283,066
$245,682

Using the extrapolated data in Table 22 to calculate the ROI over a five year
period results in the following:

ROI = ($638,773 - $10,378,370)
$10,378,370
ROI = - 0.94

Performing a similar analysis but assuming P s is the only program expense and
the number of participants increase over a five year period as described in Table 16,
results in a ROI of 0.11. Using the data collected to create a five year forecast, highlights
the significant amount of expense associated with P i even in comparison to P s.
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DISCUSSION

The findings of the evaluation are: (1) The statistically significant difference in
participant’s A1C values pre- and post-program; (2) The medical and pharmaceutical cost
difference pre- and post-program; (3) The lack of change in the pre- and post-program for
both the participant’s weight and ACO risk score; and (4) The negative results of the
financial evaluation, specifically for the cost based analysis (CBA) and the return on
investment (ROI).

The improvement in the A1C scores of the study population is the most
significant finding of the research. As a result of providing a workplace wellness program
at Self Regional Healthcare, the individuals that participated saw an improvement in the
management of diabetes as it relates to A1C scores. Through the focused efforts of health
coaches, the participants not only received assistance with how best to manage their
diabetes, they understood their current health and how behavior changes could provide
better overall health. Empowered with this information, the program population began
this improvement by positively changing their A1C values over the twelve month
program. Significant evidence exist that demonstrates the more engaged patients are in
their own care, the better the results are from health interventions or recommended
behavior changes. The fact that the population of this study saw improvement in their
A1C scores as a result of the diabetes workplace wellness program is a similar result to
previous research. The diabetes workplace wellness program provided can be built upon
by further expanding the program to Self Regional employees that are within the current
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program range but more importantly individuals that have an A1C 5.5 to 6.0 range,
considered pre-diabetic, since minimal weight loss and behavior change could prevent
these individuals from becoming diabetics. Ultimately, that is a policy goal of ACOs
which is to improve patient’s health and reduce the expense of the health care system by
having engaged patients that take responsibility for being healthier versus being
dependent on the health care industry to correct preventable health conditions.

Prior research demonstrates the ability to provide a positive return on investment
in workplace wellness programs by reducing the overall health care expense per
employee year over year and/or maintaining or reduce the expense related to provide
health insurance as an employee benefit. The medical and pharmaceutical cost difference
from pre- to post-program was the second most significant finding of the research. The
medical and pharmaceutical costs for the twenty-eight participants was $152,677 and
$114,753, respectively. The medical and pharmaceutical costs post-program was
$107,915 and $152,636, respectively. When comparing the combined costs for medical
and pharmaceutical costs pre- and post-program it was determined that the total cost
savings was $6,879.09 over the twelve month period. Evaluating the cost data for medical
and pharmaceutical expenses separately demonstrated that an almost equal cost shift
occurred. That is, while the medical costs associated with caring for the twenty-eight
participants decreased, the pharmaceutical costs over the evaluation period increased.
This is an indication of using medication to better manage diabetes for the twenty-eight
participants. As discussed previously, patient engagement in their care is a key factor in
managing a disease like diabetes. Another key component is making sure appropriate
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health care is accessible. By providing health coaches as part of the program, participants
were able to receive assistance in obtaining appropriate care in the form of improved
medication access while reducing episodic treatment by medical professionals. The
increase in pharmaceutical cost over the twelve month period while medical cost was
reduced points to engaged participants having access to appropriate disease management.
Again, tying the diabetes workplace wellness program to the policies of ACOs,
accessibility to appropriate medical care is included by requiring ACO patients to have a
medical home and reduce the expense of medical care by focusing more on preventive
care in place of expensive episodic care. While the diabetes workplace wellness program
did not eliminate diabetes for the participants, the focused care management did provide a
more stable management of the disease by reducing the amount of medical treatment
needed.

There is minimal if any correlation between the difference in program medical
cost and the reduction of A1C participant values. Based on the statistical analysis, the
efforts of the diabetes workplace wellness program did not result in a statistical
difference or correlation between the cost difference and change in participant A1C
values. This indicates that the change in cost, whether as an increase or decrease, from
pre- to post-program did not provide influence on the improvement of the A1C values for
the study group. Based on the program evaluation being a twelve month period, the A1C
value appears to be more related to the impact of the health coaches than the change in
cost associated with the medical care. Based on the improved health behaviors of the
participants, the medical cost savings is more an indication of patient engagement.
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The third most significant finding of this project is the evaluation of the pre- and
post-program weight and ACO risk score. The twenty-eight participants had a mean preprogram weight of 269 pounds. Over the twelve month period the program group
increased the mean weight to 271 pounds, though not statistically significant. This was
not an expected outcome based on the utilization of health coaches to assist each
participant with adjusting behaviors to better manage their diabetes. In addition to the
health coaches, each participant received program incentives that eliminated barriers to a
healthier lifestyle. These incentives included appropriate exercise footwear, gym
membership, and pedometers. While these incentives appeared to be of benefit during the
first quarter of the program, there utilization appeared to decline over the twelve month
program. By evaluating the quarterly step data tracked on the participant’s pedometers,
the mean daily average number of steps decreased by over 2,000 steps from the
beginning of the program to final quarter of the twelve month period. The recommended
daily average step count goal is 10,000 steps a day and the program participants
cumulative daily average step count was under 7,000 steps in quarter one and declined to
less than 5,000 steps in quarter four of the twelve month program. This result assists in
explaining why the program participant’s weight remained relatively unchanged as part
of the part of the workplace wellness program.

The ACO risk scores calculated using the CCMS tool, pre- and post-program,
were compared to determine if the reduction in medical cost and increase in
pharmaceutical cost had an impact on the participant risk scores. As reported in the
results section, the mean risk scores of program participants only changed by 0.26 over
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the twelve month program. Since the risk scores are directly related to the overall health
care cost for each participant, minimal change in the mean risk score aligns with the
marginal change in the total medical and pharmaceutical cost recorded for the program
participants. As with the weight evaluation, the results of a two-tailed T-Test comparing
risk scores did not determine a statistical difference. What is interesting, is the risk score
saw little change as a result of the program even though the A1C values for the program
are statistically different. This is an indication why evaluating a patient’s health solely
based on cost may not be the most accurate method and that even though the cost for the
twenty-eight program participants to receive medical and pharmaceutical care did not
have a significant savings the overall value used to assess diabetes, A1C, did improve. As
reimbursement within the health care industry continues to be more restrictive, the
industry is become much more cost conscious. Eliminating wasteful spending in health
care is the correct direction and is part of accountable care policy. That being said, health
care is not an industry of “widget making” and should be evaluated from multiple
disciplines such as finance, clinical efficiency, and quality of care received. By
evaluating one of these, such as finance, without consideration of the other two could
result in the improvement of the specific discipline at the expense of inefficient clinical
practice or poor quality outcomes for the patient. The other challenge of evaluating the
true impact of this study is the unknown cost avoidance for the twenty-eight participants.
Determining if the diabetes workplace wellness program prevented more costly care,
such as hospitalization due to acute ketoacidosis, would require data collection over a
longer period of time to apply national diabetes trending data in comparison to the care
required to the twenty-eight participants.
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Diabetes is reported as consuming one in every ten health care dollars in the
United States. That translates to the cost of care associated with diabetes accounts for
over a trillion dollars a year. For this reason, many health care providers understand the
value of reducing the cost associated with caring for patients with diabetes and finding
ways to reduce the number of new diabetes diagnoses on an annual basis. As discussed
previously, the ACO model attempts to achieve better engagement by individuals in
maintaining good health and reducing the expense of services needed when health care is
necessary.

The fourth significant finding of this research is the negative results of the
financial evaluation, specifically for the CBA and ROI of the diabetes workplace
wellness program. The CBA is a basic calculation used to determine if the total costs for
the diabetes workplace wellness program were lesser or greater than the total cost of
providing medical and pharmaceutical care to the twenty-eight program participants. As
reported in the Results section, the CBA Total was a loss at -$779,625.55 for the
program. The pre-program cost, which was the total medical and pharmaceutical expense,
for the participants was $267,429.99. The total cost for the diabetes workplace wellness
program, which included program personnel, software expense, incentive expense, and
total health care costs, was $1,047,055.54. For a positive CBA to occur the total program
expense would have needed to be less than $267,000.00 within the first year. Adding the
commercial ACO software and health coach staff made it very difficult to achieve a
positive CBA. Both of these program components cost, ACO software and staff, cost the
program $573,640.64 and $117,944.00, respectively. Removing those two program
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expenses would have resulted in a negative CBA of -$88,040.91 for the first year of the
program. While the cost of the health coach staff and commercial software had a
significant impact on the overall CBA, it would be difficult to eliminate both of these
components of the program. The health coach employees worked directly with the
patients to eliminate barriers to receiving appropriate care and drive higher engagement
and responsibility by the participants. Without the health coach involvement, the A1C
values may not have improved as they did over the twelve month program. The
commercial software expense is an unfortunate reality of health care information
technology. The health care industry is very expensive and the non-direct patient care
tools used are no exception. The software utilized in health care is very expensive and
should be an area of focus for information technology professionals. As new software is
being considered for purchase, information technology professionals should first evaluate
what the return on investment will be by adding new tools. In many cases, software is
purchased solely on new functionality with little consideration of how net revenues will
be improved. If software is purchased without the financial analysis, the additional
functionality could easily have a negative impact on the net revenue for the organization
which could lead to increased fees for services to maintain operating margins. Once it is
determined that the new functionality will be beneficial to clinical efficiency, quality
outcomes, and organizational finances, information technology leaders should find ways
to reduce duplication of products and identify the best pricing to avoid utilizing capital
that is best spent on direct patient care tools. These types of expenses all relate back to
the overwhelming expense patients incur when receiving care in the current health care
model.
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The ROI for the diabetes workplace wellness program has similar results to the
CBA calculation. The ROI calculation is a formula that compares the investment gain and
investment cost to determine if the program provided a positive or negative return on the
funds invested to initiate the program. With the investment cost being so much greater
than the investment gain in the twelve months of the program, it is not a surprise that the
program had a – 99% ROI. As it was explained with the CBA results, the capital expense
of adding the commercial ACO software and the staffing expense significantly reduced
the ability of the program to generate a positive ROI. That coupled with the cost savings
for medical and pharmaceutical expense only totaling $6,879.09, a negative ROI is to be
expected. As mentioned previously, estimating the ROI of new information technology
solutions should be completed prior to purchase and implementation of the product. In
the new health care reimbursement model, all payers in the industry are reducing the
reimbursement for care provided and hold health care organizations accountable for
finding cost savings. At the same time health care legislation is challenging organizations
to be more transparent with price and quality which requires new systems and services to
be put in place, such as diabetes workplace wellness programs. The challenge of this
model is the funding for service expansion is being reduced while capital investments are
being increased. The diabetes workplace wellness program reviewed in this research has
demonstrated an improvement in participant A1C values within the first twelve months of
the program which is a success. The negative ROI indicates more money was spent than
saved but typically ROI’s are determined over a much longer period of time allowing for
increased savings to offset the initial expense of establishing the program. Even after
expanding the program via the sensitivity analysis, which allowed for greater program
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time and more participants, only improved the ROI to -94%. Only by eliminating the
program incentive expense over a five year period with program participant growth
resulted in a positive ROI of 11%. Using the ROI calculation listed above could be
considered too harsh of an evaluation for the purposes of this research, but using a
financial ROI evaluation is a reality of the current health care industry. Not all processes
in health care are driven by financial evaluations but ignoring these types of evaluations
has a potential for greater impact than anticipated.

Limitations of the research associated with the diabetes workplace wellness
program range from a small participant population to assuming the cost of a commercial
ACO risk tool in the first year. The population used for the program originally was slated
for fifty participants from a single organization but was reduced to twenty-eight
participants due to a lack of data or failure of the participant to enroll. The fact that a
small population from a single organization was used makes it difficult to generalize the
findings. Most of the research reviewed in preparation for this project used populations
that numbered in the tens to hundreds of thousands and were mostly focused on
workplace wellness programs without ACO software. When considering the sample size
of the research, it is almost important to note the impact of the law of large numbers and
how a greater participant population would have an impact on the results of similar
research. A second limitation was the program was developed as a pilot to assess the
benefit of the ACO software in combination with a workplace wellness program. While
pilots are beneficial to perform initial evaluations, that are also usually the first effort to
develop processes and procedures. Developing the functionality of the program at the
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same time of evaluating the program resulted in unexpected issues that would impact the
outcome of the program such as adding or removing participants of the program to
maintain the original program population. A third limitation, was the length of the study.
Twelve months for a financial evaluation of a small population is challenging. Especially
when the majority of program expenses are incurred in the first twelve months. Not
accounting for the deflation or inflation of costs over the twelve month period is the
fourth limitation and it should be noted that the costs of the medical and pharmaceutical
care were realized and not observed. The fifth and possibly greatest limitation to the
program was the cost of the commercially ACO software. Utilizing a fully functional,
large population tool to assess the risk of a small population created excessive financial
burden on both the CBA and ROI analysis.

Future research that should be attempted based on the findings of this project
would be to evaluate the financial outcome of an identical project with a much larger
population over a five year time frame. The five year time frame is the standard length of
time to fully expense capital software purchases versus assessing the total software cost
in the first year. Additionally, it would be interesting to understanding if a program based
on increased pharmaceutical care for diabetics would provide the same benefit as this
diabetes workplace wellness program. Based on the results of the program, it appears that
the increase in pharmaceutical expense reduced the medical expense for the participants
of the program and the overall A1C. This may be an artifact of the limited population size
but is worth investigating further.
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In conclusion, the answer to the research question, “Can using an ACO
commercially available software tool and a diabetes workplace wellness management
program be combined to identify 1 year ROI in a sample of patients within an average
size institution?” is yes, it was possible to calculate an ROI but resulted in a negative
return on investment. The research hypothesis, “Utilizing the tools provided with both
commercially available ACO software and workplace wellness program structure, the
cost associated with managing the health care of individuals diagnosed with diabetes will
be reduced” must be rejected based on both the negative CBA and ROI results. That
being said, understanding the dramatic impact diabetes has on individuals diagnosed with
the disease, health care resources, and overall expense to the health care system, this
research provides evidence that the ACO model combined with a workplace wellness
program does address the impact on the individual by improving the management of the
disease, as seen by the reduction in A1C values, and reduces the burden on health care
resources by reducing the need for medical care by properly utilizing pharmaceutical care
to manage the individual’s diabetes. The program results also demonstrate that to
positively impact the financial burden on the health care system, the ACO model is a long
term proposition that requires substantial and continuous effort to modify the behaviors
of individuals and increase their engagement in preventative care versus episodic care.
Being able to move the A1C value in the right direction is the greatest success of this
research. It is important that even though the financial evaluations of the program
indicate a less than positive result, I believe this is more a reflection of the length of time
and size of population of the program than determinant of program value.
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